0000883984-20-000014 | 10-K | XBRL Viewer

Derivatives and Hedging Activities (Tables)

12 Months Ended

Dec. 31, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]

The following table presents the fair values of our derivative instruments included within the Consolidated Balance Sheets (in thousands):



	Derivatives
		December 31,
	Consolidated Balance Sheet Location	2019		2018
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:	Prepaid expenses and other current assets	$	2,366	$	187
	Other assets	—		545
Total derivatives designated as cash flow hedging instruments		$	2,366	$	732

The following table presents the amounts affecting the Consolidated Statements of Operations (in thousands):



		Year Ended December 31,
	Line Item in the Consolidated Statements of Operations	2019		2018		2017
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	916	$	743	$	885

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]

We recognized the following gains on our foreign exchange contract designated as a cash flow hedge (in thousands):



	Amount of Gain Recognized in Other Comprehensive Income on Derivatives						Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Year Ended December 31,							Year Ended December 31,
	2019		2018		2017		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2019		2018		2017
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	2,550	$	2,063	$	296	Cost of goods sold	$	916	$	743	$	885
Total derivatives designated as cash flow hedging instruments	$	2,550	$	2,063	$	296		$	916	$	743	$	885

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 268,670,000	$ 344,781,000
Short-term investment securities	23,967,000	37,329,000
TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES	292,637,000	382,110,000
Accounts receivable, net of allowance for doubtful accounts of $20,219 at December 31, 2019 and $5,768 at December 31, 2018	202,219,000	176,298,000
Inventories	337,640,000	311,163,000
Prepaid income taxes	15,720,000	11,348,000
Prepaid expenses and other current assets	33,981,000	46,117,000
Total current assets	882,197,000	927,036,000
PROPERTY AND EQUIPMENT, net	456,085,000	432,641,000
Operating Lease, Right-of-Use Asset	34,465,000	0
LONG-TERM INVESTMENT SECURITIES	0	2,025,000
GOODWILL	31,245,000	11,195,000
INTANGIBLE ASSETS, net	211,408,000	133,421,000
DEFERRED INCOME TAXES	27,998,000	38,654,000
Other Assets	48,984,000	40,419,000
TOTAL ASSETS	1,692,382,000	1,585,391,000
CURRENT LIABILITIES:
Accounts payable	128,629,000	120,469,000
Accrued liabilities	117,776,000	128,820,000
Income tax payable	2,063,000	0
Total current liabilities	248,468,000	249,289,000
Contingent Earn-out Liability	17,300,000	47,400,000
OTHER LONG-TERM LIABILITIES	32,820,000	20,592,000
DEFERRED INCOME TAXES	2,091,000	721,000
INCOME TAX LIABILITY	14,459,000	3,734,000
COMMITMENTS AND CONTINGENCIES	0	0
STOCKHOLDERS' EQUITY:
Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none	0	0
Common stock, $0.10 par value - Authorized-80,000 shares; Issued 20,743 shares at December 31, 2019 and 20,492 at December 31, 2018 and outstanding 20,742 shares at December 31, 2019 and 20,491 shares at December 31, 2018	2,074,000	2,049,000
Additional paid-in capital	668,947,000	657,899,000
Treasury Stock, Value	(157,000)	(95,000)
Retained earnings	721,782,000	620,747,000
Accumulated other comprehensive loss	(15,402,000)	(16,945,000)
Total stockholders' equity	1,377,244,000	1,263,655,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	1,692,382,000	1,585,391,000
Allowance for doubtful accounts	$ 13,487,989	$ 5,768,045
Convertible preferred stock, par value	$ 1	$ 1
Convertible preferred stock, authorized shares	500,000	500,000
Convertible preferred stock, issued shares	$ 0	$ 0
Convertible preferred stock, outstanding shares	0	0
Common stock, par value	$ 0.1	$ 0.1
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	20,742,894	20,491,637
Common stock, shares outstanding	20,742,044	20,491,229
Treasury Stock, Common, Shares	850	408

Consolidated Statements of Stockholders Equity - USD ($) $ in Thousands	Total	Common Stock Shares [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, Shares at Dec. 31, 2016		16,338,000
Balance at Dec. 31, 2016	$ 660,155		$ 1,633	$ 162,828	$ (14)	$ 516,980	$ (21,272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock and exercise of stock options, shares issued		676,000
Issuance of restricted stock and exercise of stock options, including excess income tax benefits	32,003		66	27,866	4,071
Treasury Stock, Shares		(27,000)
Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations	(4,057)			0	(4,057)
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		3,200,000
Issuance of common stock for acquisitions	413,139		320	412,819
Employee stock purchase plan, shares issued		23,000
Proceeds from employee stock purchase plan	2,705		2	2,703	0
Stock compensation	19,352			19,352
Other comprehensive income, net of tax	6,313						6,313
Net Income	68,644					68,644
Balance at Dec. 31, 2017	1,198,254		2,021	625,568	0	585,624	(14,959)
Balance, Shares at Dec. 31, 2017		20,210,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock and exercise of stock options, shares issued		307,000
Issuance of restricted stock and exercise of stock options, including excess income tax benefits	14,275		28	8,090	6,157
Treasury Stock, Shares		(26,000)
Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations	(6,252)			0	(6,252)
Proceeds from employee stock purchase plan	0
Stock compensation	24,241			24,241
Other comprehensive income, net of tax	(1,986)						(1,986)
Net Income	28,793					28,793
Balance at Dec. 31, 2018	$ 1,263,655		2,049	657,899	(95)	620,747	(16,945)
Balance, Shares at Dec. 31, 2018	20,491,229	20,491,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative Effect of New Accounting Principle in Period of Adoption	$ 6,330
Issuance of restricted stock and exercise of stock options, shares issued		331,000
Issuance of restricted stock and exercise of stock options, including excess income tax benefits	7,732		25	(10,870)	18,577
Treasury Stock, Shares		(80,000)
Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations	(18,639)			0	(18,639)
Issuance of common stock for acquisitions	0
Proceeds from employee stock purchase plan	0
Stock compensation	21,918			21,918
Other comprehensive income, net of tax	1,543						1,543
Net Income	101,035					101,035
Balance at Dec. 31, 2019	$ 1,377,244		$ 2,074	$ 668,947	$ (157)	$ 721,782	$ (15,402)
Balance, Shares at Dec. 31, 2019	20,742,044	20,742,000

General and Summary of Significant Accounting Policies Future Estimated Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 21,692
Finite-Lived Intangible Assets, Amortization Expense, Year Two	22,587
Finite-Lived Intangible Assets, Amortization Expense, Year Three	22,303
Finite-Lived Intangible Assets, Amortization Expense, Year Four	21,461
Finite-Lived Intangible Assets, Amortization Expense, Year Five	21,371
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	88,003
Finite-Lived Intangible Assets, Net	$ 197,417	$ 125,186

Revenue Contract Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
COntract Liability Rollforward [Roll Forward]
Contract with Customer, Liability	$ (4,282)	$ (7,066)
Contract with Customer, Liability	(4,855)	(4,282)
Equipment revenue [Member]
COntract Liability Rollforward [Roll Forward]
Increase (Decrease) in Deferred Revenue	(8,807)	(6,696)
Deferred Revenue, Additions	8,794	4,196
Software revenue [Member]
COntract Liability Rollforward [Roll Forward]
Increase (Decrease) in Deferred Revenue	(3,953)	(6,553)
Deferred Revenue, Additions	$ 4,539	$ 6,269

Acquisitions (Notes)

12 Months Ended

Dec. 31, 2019

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

ACQUISITIONS

2019 Acquisitions

On November 2, 2019, we acquired 100% interest in Pursuit for cash consideration of approximately $75.0 million. Additionally, Pursuit's equity holders are potentially entitled up to $50.0 million in additional cash consideration contingent upon the achievement of certain sales and gross profit targets for specific customers. The earn-out paid will be calculated as a percentage of gross profit achieved during the earn-out period against a pre-determined target gross profit. However, the earn-out is not to exceed $50.0 million. The acquisition of Pursuit and their ClearGuard HD is a natural extension of our needlefree IV connector and other infection control technologies, which together provides us the best of breed solutions.

Preliminary Purchase Price

The following table summarizes the preliminary purchase price and the preliminary allocation of the purchase price related to the assets and liabilities purchased (in thousands):



Cash consideration for acquired assets, net	$	71,533
Fair value of contingent consideration	17,300
Total Estimated Consideration	$	88,833

Preliminary Purchase Price Allocation:
Trade receivables	$	973
Inventories	2,464
Prepaid expenses and other current assets	74
Property, plant and equipment	609
Intangible assets⁽¹⁾	82,300
Accounts payable	(215		)
Accrued liabilities	(2,065		)
Total identifiable net assets acquired	$	84,140
Goodwill - not tax deductible	19,116
Deferred tax liability	(14,423		)
Estimated Purchase Consideration	$	88,833

^{____________________________________________}

⁽¹⁾ Identifiable intangible assets includes $69.0 million of developed technology, $10.8 million of trade name and $2.5 million of non-compete agreement. The weighted amortization period for the total identifiable intangible assets is approximately fifteen years for developed technology, and trade name the weighted amortization period is fifteen years, and for the non-compete agreement the weighted amortization period is three years.

The identifiable intangible assets acquired have been valued as Level 3 assets at fair market value. The estimated fair value of identifiable intangible assets were developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; and estimated useful lives. Fixed assets were valued with the consideration of remaining economic lives. The raw materials inventory was valued at historical cost and adjusted for any obsolescence and finished goods inventory was valued at estimated sales proceeds less a nominal profit and costs to sell. The trade receivables, prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature.

The above purchase price and purchase price allocation are preliminary and subject to finalization.

During 2019, we also acquired a small foreign distributor for approximately $4.6 million in cash.

Significant 2017 Acquisitions

On February 3, 2017, we acquired 100% interest in Pfizer's HIS business for total cash consideration of approximately $260.0 million (net of estimated working capital adjustments paid at closing), which was financed with existing cash balances and a $75 million three-year interest-only seller note. We also issued 3.2 million shares of our common stock. The fair value of the common shares issued to Pfizer was determined based on the closing price of our common shares on the closing date, discounted to reflect a contractual lock-up period whereby Pfizer cannot transfer the shares, subject to certain exceptions, until the earlier of (i) the expiration of Pfizer’s services to us in the related transitional services agreement or (ii) eighteen months from the closing date. Additionally, Pfizer was entitled up to an additional $225 million in cash contingent consideration based on the achievement of performance targets for the combined company for the three years ending December 31, 2019 ("Earnout Period"). The Earn-out Period ended on December 31, 2019 and we did not meet the required performance targets in order to pay any of the earn-out. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. The acquisition of the HIS business, which includes IV pumps, solutions and consumable devices complements our pre-existing business by creating a company that has a complete infusion therapy product portfolio. We believe that the acquisition significantly enhances our global footprint and platform for continued competitiveness and growth.

With the acquisition of HIS, pre-existing long-term supply and distribution contracts between ICU and HIS were effectively terminated.

Deferred Closings

In the Asset Purchase Agreement between us and Pfizer, we agreed to defer the local closing of the HIS business in certain foreign jurisdictions (the “Deferred Closing Businesses”) for periods ranging by jurisdiction from 3 to 12 months after the February 3, 2017 closing date (the "Deferred Closing Period"). The net assets in these jurisdictions represent an immaterial portion of the total HIS business net assets.

At the February 3, 2017 HIS business transaction closing, we entered into a Net Economic Benefit Agreement with Pfizer under which we agreed that (i) during the Deferred Closing Period, the economic benefits and burdens of the Deferred Closing Businesses are for our account, and we are to be treated as the beneficial owner of the Deferred Closing Businesses and (ii) Pfizer would continue to operate the Deferred Closing Businesses under our direction.

All of the deferred closing businesses were effectively closed in 2017.

Purchase Price

The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets and liabilities purchased (in thousands, except per share data):



Cash consideration for acquired assets	$	180,785
Fair value of Seller Note	75,000
Fair value of contingent consideration payable to Pfizer (long-term)	19,000

Issuance of ICU Medical, Inc. common shares:
Number of shares issued to Pfizer	3,200
Price per share (ICU's trading closing share price on the Closing Date)	$	140.75
Market price of ICU shares issued to Pfizer	$	450,400
Less: Discount due to lack of marketability of 8.3%	(37,261		)
Equity portion of purchase price	413,139
Total Consideration	$	687,924

Purchase Price Allocation:
Cash and cash equivalents	$	31,082
Trade receivables	362
Inventories	417,622
Prepaid expenses and other assets	13,911
Property, plant and equipment	288,134
Intangible assets⁽¹⁾	131,000
Other assets	29,270
Accounts payable	(12,381		)
Accrued liabilities	(47,936		)
Long-term liabilities⁽²⁾	(67,170		)
Total identifiable net assets acquired	$	783,894
Deferred tax, net	(25,080		)
Estimated Gain on Bargain Purchase	(70,890		)
Estimated Purchase Consideration	$	687,924

______________________________

⁽¹⁾ Identifiable intangible assets includes $48 million of customer relationships, $44 million of developed technology - pumps and dedicated sets, $34 million of developed technology - consumables, and $5 million of in-process research and development ("IPR&D"). The weighted amortization period for the total identifiable assets is approximately nine years, for customer relationships the weighted amortization period is eight years, for the developed technology - pumps and dedicated sets the weighted amortization period is ten years and for the developed technology - consumables the weighted amortization period is twelve years. The IPR&D is non-amortizing until the associated research and development efforts are complete.

⁽²⁾Long-term liabilities primarily consisted of contract liabilities, product liabilities and long-term employee benefits.

The fair value of the assets acquired and liabilities assumed exceeded the fair value of the consideration to be paid resulting in a bargain purchase gain. Before recognizing a gain on a bargain purchase, we reassessed the methods used in the purchase accounting and verified that we had identified all of the assets acquired and all of the liabilities assumed, and that there were no additional assets or liabilities to be considered. We also reevaluated the fair value of the contingent consideration transferred to determine that it was appropriate. We determined that the bargain purchase gain was primarily attributable to

expected restructuring costs as well as a reduction to the initially agreed upon transaction price caused primarily by revenue shortfalls across all market segments of the HIS business, negative manufacturing variance due to the drop in revenue and higher operating and required stand up costs, when compared to forecasts of the HIS business at the time that the purchase price was agreed upon. After the continuing review of the product demand and operations of the HIS Business, including the resulting expected restructuring activities, we forecasted our estimated Adjusted EBITDA from the HIS business in 2017 to be $35 million - $40 million, which was considerably lower than the forecast contemplated in initial negotiations with Pfizer, which resulted in an estimated fair value of $19 million related to the $225 million earn out. The bargain purchase gain is separately stated below income from operations in the accompanying consolidated statements of operations for the year ended December 31, 2017.

The identifiable intangible assets and other long-lived assets acquired have been valued as Level 3 assets at fair market value. The estimated fair value of identifiable intangible assets were developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; customer retention rates; and estimated useful lives. Fixed assets were valued with the consideration of remaining economic lives. The raw materials inventory was valued at historical cost and adjusted for any obsolescence, the work in process was valued at estimated sales proceeds less costs to complete and costs to sell, and finished goods inventory was valued at estimated sales proceeds less a nominal profit and costs to sell. The prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature.

Unaudited Pro Forma Information

The pro forma financial information in the table below summarizes the combined results of operations for ICU and HIS as though the companies were combined as of the beginning of fiscal 2016. The pro forma financial information includes the business combination accounting effects resulting from this acquisition including our amortization charges from acquired intangible assets, nonrecurring expense related to the fair value adjustment to acquisition-date inventory, acquisition and integration-related costs, interest expense on the Pfizer seller note and the related tax effects.



(In millions)	Revenue		Earnings
Actual from 2/3/2017 - 12/31/2017⁽³⁾	$	1,062	*
2017 supplemental pro forma from 1/1/2017 - 12/31/2017⁽¹⁾⁽²⁾	$	1,373	$	91

______________________________

* Impracticable to calculate.

⁽¹⁾2017 supplemental pro forma earnings were adjusted to exclude $66.3 million of nonrecurring expense related to the fair value adjustment to acquisition-date inventory, $59.2 million of acquisition and integration-related costs and $70.9 million in bargain purchase gain.

⁽²⁾Unaudited.

⁽³⁾ Amount represents activity of HIS from the date of the acquisition.

Restructuring, Strategic Transaction and Integration (Details 1) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring, strategic transaction and integration expenses	$ 41,100	$ 80,574	$ 105,390	$ 77,967
Restructuring Charges		8,400	$ 4,500	$ 18,800
Restructuring and Related Cost, Cost Incurred to Date		$ 25,100

Leases Supplemental Balance Sheet Lease information (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Operating Lease, Right-of-Use Asset	$ 34,465	$ 0
Operating Lease, Liability, Current	7,362	$ 0
Operating Lease, Liability, Noncurrent	28,896
Operating Lease, Liability	$ 36,258
Operating Lease, Weighted Average Remaining Lease Term	6 years
Operating Lease, Weighted Average Discount Rate, Percent	5.57%

General and Summary of Significant Accounting Policies Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill [Roll Forward]
GOODWILL	$ 11,195	$ 12,357	$ 5,577
Goodwill, Acquired During Period	20,026	1,300	6,536
Goodwill, Foreign Currency Translation Gain (Loss)	24		244
Goodwill, Purchase Accounting Adjustments		(2,462)
GOODWILL	31,245	11,195	$ 12,357
Medical Australia Limited [Member]
Goodwill [Roll Forward]
Goodwill, Purchase Accounting Adjustments		1,900
Pursuit Vascular, Inc. [Member]
Goodwill [Roll Forward]
Goodwill, Acquired During Period	19,100
Tru Process [Member]
Goodwill [Roll Forward]
Goodwill, Acquired During Period		$ 1,300
Other Acquisition [Member]
Goodwill [Roll Forward]
Goodwill, Acquired During Period	$ 900

Prepaids and Other Current Assets (Notes)

12 Months Ended

Dec. 31, 2019

Prepaid Expense and Other Assets, Current [Abstract]

Other Current Assets [Text Block]

PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following (in thousands):



	December 31,
	2019		2018
Deposits	$	1,375	$	1,087
Other prepaid expenses and receivables	13,778		12,476
Receivables from Pfizer related to HIS business acquisition⁽¹⁾	—		20,137
Deferred costs	3,332		1,951
Prepaid insurance and property taxes	5,450		2,666
VAT/GST receivable	4,422		5,072
Deferred tax charge	1,266		1,180
Other	4,358		1,548
	$	33,981	$	46,117

___________________________________

⁽¹⁾ We reclassified the December 31, 2018 related-party receivable due from Pfizer to prepaid expenses and other current assets for current year presentation purposes. During the years 2018 and 2017, Pfizer was a related party to us as we issued 3.2 million shares of our common stock as partial consideration for the 2017 acquisition of HIS. As of December 31, 2018, Pfizer had sold all of its shares of our common stock. During 2018, in connection with the sale of the 2.5 million of the shares Pfizer held, we incurred a one-time fee payable to Pfizer in the amount of $8.0 million included in restructuring, strategic transaction and integration expense in our consolidated statement of operations.

Related-party revenue for goods manufactured for Pfizer under our Manufacturing and Supply Agreements with Pfizer (see Note 16, Collaborative and Other Arrangements) was $78.2 million and $72.4 million during the years 2018 and 2017, respectively, and the cost of product manufactured by Pfizer for us under those agreements was $81.0 million and $70.2 million during the years 2018 and 2017, respectively.

Acquisitions Hospira Contingent Consideration (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2017
Business Acquisition, Contingent Consideration [Line Items]
Business Combination, Contingent Consideration, Liability, Noncurrent	$ 17,300	$ 19,000
Hospira [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination, Contingent Consideration, Liability, Noncurrent		19,000
contingent consideration gross	$ 225,000	225,000
Minimum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Adjusted EBITDA		35,000
Maximum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Adjusted EBITDA		$ 40,000

Share Based Award Share Award data (Details)	Dec. 31, 2019 $ / shares
Share award data [Abstract]
Share Price	$ 187.12

Derivatives and Hedging Activities (Details) $ in Millions, $ in Millions	Dec. 31, 2019 USD ($)	Dec. 31, 2019 MXN ($)
Derivative [Line Items]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ (2.4)
Hedge 1 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	20.01	20.01
Hedge 2 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	20.43	20.43
Hedge 3 [Member] [Member]
Derivative [Line Items]
Derivative, Notional Amount		$ 364.8
Derivative, Forward Exchange Rate	22.109	22.109

Share Based Award Stock Option Plans (Details) - shares	12 Months Ended
Share Based Award Stock Option Plans (Details) - shares	Dec. 31, 2019	Dec. 31, 2011
2011 Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,925,000	650,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	3,275,000
Shares transferred from superseded plan	263,300
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	4,188,300
2003 Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	248,700
2001 Director's Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	750,000
Share-based Payment Arrangement, Option [Member] \| 2014 Inducement Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	182,366
Restricted Stock Units (RSUs) [Member] \| 2014 Inducement Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	68,039

Income Taxes Deferred income tax assets (liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets and liabilities [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards	$ 0	$ 12,686
Non-current deferred tax asset	67,961	76,571
Deferred Tax Assets, Net	25,907	37,933
Non-current deferred tax asset, gross total [Member]
Deferred tax assets and liabilities [Line Items]
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other	2,632	11,109
Deferred Tax Assets, Other	0	12,451
Noncurrent deferred tax asset - acquired future tax deductions	8,711	10,722
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	9,654	10,775
Deferred Tax Assets, Unrealized Currency Losses	2,716	3,108
Noncurrent deferred tax asset - tax credits state	11,331	14,470
Deferred Tax Assets, Inventory	4,305	5,674
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	4,242	830
Noncurrentdeferredtaxassetaccruedrestructuring	7,072	182
Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions	20,975	0
Deferred Tax Assets, Valuation Allowance, Noncurrent	(3,677)	(5,436)
Noncurrent deferred tax liability [Member]
Deferred tax assets and liabilities [Line Items]
Noncurrent deferred tax liability - depreciation and amortization	23,839	35,387
Noncurrent deferred tax liability - state income taxes	2,600	2,639
Noncurrent deferred tax liability - foreign	997	612
Deferred Tax Liabilities, Net	42,054	38,638
Deferred tax liability, change in accounting method	$ 14,618	$ 0

Geographic Information and Significant Customers Long Lived Assets by Geographic Location (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 776,240	$ 694,864
COSTA RICA
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	96,442	81,920
Mexico Property and Equipment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	69,141	64,242
Other LATAM [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	31,905	22,828
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	4,769	4,545
Italy Property and Equipment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	7,921	7,819
SPAIN
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	6,411	6,516
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	3,135	2,427
Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	17,200	15,152
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	236,924	205,449
United States property and equipment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 539,316	$ 489,415

General and Summary of Significant Accounting Policies Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Equity Securities, Amortized Cost Basis	$ 23,967	$ 39,354
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax	0	0
Available-for-sale Securities	23,967	39,354
Long-term Investments [Domain]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Equity Securities, Amortized Cost Basis	0	2,025
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax	0	0
Available-for-sale Securities	0	2,025
Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Equity Securities, Amortized Cost Basis	23,967	37,329
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax	0	0
Available-for-sale Securities	$ 23,967	$ 37,329

Restructuring, Strategic Transaction and Integration Strategic Transaction and Integration Expenses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Strategic Transaction and Integration	$ 72.2	$ 100.9	$ 59.2
Supplychainrestructuringcosts	22.1
Cleanupcosts	$ 12.7

General and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Business Description and Basis of Presentation [Text Block]

Basis of Presentation and Preparation

ICU Medical, Inc. ("ICU" or "we"), a Delaware corporation, operates in one business segment engaged in the development, manufacturing and sale of innovative medical devices used in vascular therapy, and critical care applications. We are one of the world's leading pure-play infusion therapy companies with a wide-ranging product portfolio that includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. We sell the majority of our products through our direct sales force and through independent distributors throughout the U. S. and internationally. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers. The manufacturing for all product groups occurs in Salt Lake City, Utah, Austin, Texas, Mexico and Costa Rica.

All subsidiaries are wholly owned and are included in the consolidated financial statements. All intercompany accounts and transactions have been eliminated. Results of operations of companies purchased are included from the dates of acquisition.

Use of Estimates, Policy [Policy Text Block]

Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and have original maturities of three months or less from the date of purchase as cash equivalents.

Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]

Accounts receivable are stated at net realizable value. An allowance is provided for estimated collection losses based on an assessment of various factors. We consider prior payment trends, the age of the accounts receivable balances, financial status and other factors to estimate the cash which ultimately will be received. Such amounts cannot be known with certainty at the financial statement date. We regularly review individual past due balances for collectability.

Inventory, Policy [Policy Text Block]

Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.

Property, Plant and Equipment, Policy [Policy Text Block]

All property, plant and equipment are stated at cost. We use the straight-line method for depreciating property, plant and equipment over their estimated useful lives. Estimated useful lives are:



Buildings	15 - 30 years
Building improvements	15 - 30 years
Machinery, equipment and molds	2 - 15 years
Furniture, fixtures and office equipment	2 - 5 years
Computer equipment and software	3 - 5 years
Instruments placed with customers	3 - 10 years

We capitalize expenditures that materially increase the life of the related assets; maintenance and repairs are expensed as incurred. The costs and related accumulated depreciation applicable to property, plant and equipment sold or retired are removed from the accounts and any gain or loss is reflected in the statements of operations at the time of disposal. Depreciation expense was $59.3 million, $58.1 million and $51.6 million in the years ended December 31, 2019, 2018 and 2017, respectively.

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

We test goodwill for impairment on an annual basis in the month of November. If the carrying amount of goodwill exceeds the implied estimated fair value, an impairment charge to current operations is recorded to reduce the carrying value to the implied estimated fair value.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-Lived Assets

We periodically evaluate the recoverability of long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When indicators of impairment are present, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of the underlying asset is adjusted to fair value if the sum of the expected discounted cash flows is less than book value. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and discount rates, reflecting varying degrees of perceived risk.

Investment, Policy [Policy Text Block]

Investment Securities

Short-term investments, exclusive of cash equivalents, are marketable securities intended to be sold within one year and may include trading securities, available-for-sale securities, and held-to-maturity securities (if maturing within one year at the time of acquisition). Long-term investments are marketable securities intended to be sold after one year and may include trading securities, available-for-sale securities, and held-to-maturity securities.

Our investment securities are considered available-for-sale and are “investment grade” and carried at fair value. Our investments currently consist of corporate bonds. Available-for-sale securities are recorded at fair value, and unrealized holding gains and losses are recorded, net of tax, as a component of accumulated other comprehensive income (loss). Unrealized losses on available-for-sale securities are charged against net earnings when a decline in fair value is determined to be other than temporary. Our management reviews several factors to determine whether a loss is other than temporary, such as the length and extent of the fair value decline, the financial condition and near term prospects of the issuer, and for equity investments, our intent and ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. For debt securities, management also evaluates whether we have the intent to sell or will likely be required to sell before its anticipated recovery. Realized gains and losses are accounted for on the specific identification method. There have been no realized gains or losses on the disposal of investments. Our investments mature in 2020. All short-term investment securities are all callable within one year.

Income Tax, Policy [Policy Text Block]

Income Taxes

Deferred taxes are determined based on the differences between the financial statements and the tax bases using rates as enacted in the laws. A valuation allowance is established if it is “more likely than not” that all or a portion of the deferred tax assets will not be realized.

We recognize interest and penalties related to unrecognized tax benefits in the tax provision. We recognize liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. We have not recorded any material interest or penalties during any of the years presented.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency

Generally, the functional currency of our international subsidiaries is the local currency. Generally, we translate the financial statements of these subsidiaries to U.S. dollars at the exchange rate in effect at the balance sheet date and revenues and expenses are translated at the average monthly exchange rates during the year. Certain of our international subsidiaries consolidate first with another subsidiary that utilizes a functional currency other than U.S. dollars. In those cases, we follow a step by step translation process utilizing the same sequence as the consolidation process. Translation adjustments are recorded as a component of accumulated other comprehensive income (loss), a separate component of stockholders' equity on our consolidated balance sheets and the effect of exchange rate changes on cash and cash equivalents are reflected on our consolidated statements of cash flows. Gains and losses for transactions denominated in a currency other than the functional currency of the entity are included in our statements of operations in other income (expense), net. Foreign currency transaction (gains) losses, net were $(0.7) million in 2019, $7.9 million in 2018 and $1.8 million in 2017.

Revenue [Policy Text Block]

Revenue Recognition

We recognize revenues when we transfer control of promised goods to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods. We offer certain volume-based rebates to our distribution customers, which we consider variable consideration when calculating the transaction price. We also provide chargebacks to distributors that sell to end-customers at prices determined under a contract between us and the end-customer.

Chargebacks are the difference between prices we charge our distribution customers and contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the most likely rebate and chargeback amounts for use in determining the transaction price, we use information available at the time and our historical experience. We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available and our historical experience. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.

The vast majority of our sales of Infusion Consumables, Infusion Systems, IV Solutions and Critical Care products are sold on a standalone basis and control of these products transfers to the customer upon shipment.

Our software license renewals are considered to be transferred to a customer at a point in time at the start of each renewal period, therefore revenue is recognized at that time.

Arrangements with Multiple Deliverables

In certain circumstances, we enter into arrangements in which we provide multiple deliverables to our customers. These bundled arrangements typically consist of the sale of infusion systems equipment, along with annual software licenses and related software implementation services, as well as infusion consumables, IV solutions and extended warranties.

Our most significant judgments related to these arrangements are (i) identifying the various performance obligations and (ii) estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method. Revenue related to the bundled equipment, software and software implementation services are typically combined into a single performance obligation and recognized upon implementation. As annual software licenses are renewed, we recognize revenue for the license at a point in time, at the start of each annual renewal period. The transaction price allocated to the extended service-type warranty is recognized as revenue over the period the warranty service is provided. Consumables and solutions are separate performance obligations, recognized at a point in time.

Shipping and Handling Cost, Policy [Policy Text Block]

Shipping Costs

Costs to ship finished goods to our customers are included in cost of goods sold on the consolidated statements of operations.

Advertising Cost [Policy Text Block]

Advertising Expenses

Advertising expenses are expensed as incurred and reflected in selling, general and administrative expenses in our consolidated statements of operations and were $0.1 million in 2019, $0.6 million in 2018 and $0.2 million in 2017.

Pension and Other Postretirement Plans, Policy [Policy Text Block]

Post-retirement and Post-employment Benefits

We sponsor a Section 401(k) retirement plan ("plan") for employees. Our contributions to our 401(k) plan were approximately $11.4 million in 2019, $11.4 million in 2018 and $10.3 million in 2017. As a result of the Hospira Infusion Systems ("HIS") acquisition, we assumed certain post-retirement and post-employment obligations related to employees located in certain international countries. These obligations are immaterial to our financial statements taken as a whole.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

The majority of our research and development costs are expensed as incurred. In certain circumstances when an asset will have an alternative future use we capitalize the costs related to those assets. Research and development costs include salaries and related benefits, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs.

Earnings Per Share, Policy [Policy Text Block]

Net Income Per Share

Net income per share is computed by dividing net income by the weighted average number of common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average number of common shares outstanding plus dilutive securities. Dilutive securities include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive, where their exercise price exceeds the average market price of the common stock are not included in the treasury stock method calculation.

General and Summary of Significant Accounting Policies Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Raw Materials	$ 119,709	$ 104,104
Work in Process	39,515	52,909
Finished Goods	178,416	154,150
Total	$ 337,640	$ 311,163

Acquisitions Pro Forma (Details) - USD ($) $ in Thousands	12 Months Ended
Acquisitions Pro Forma (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 1,062
Business Acquisition, Pro Forma Revenue			1,373
Business Acquisition, Pro Forma Net Income (Loss)			91
Business Combination, Bargain Purchase, Gain Recognized, Amount	$ 0	$ 0	70,890
Inventories [Member]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			66,300
Acquisition-related Costs [Member]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Business Acquisition, Transaction Costs			$ 59,200

Selected Quarterly Financial Data - Unaudited

12 Months Ended

Dec. 31, 2019

Quarterly Financial Data - Unaudited [Abstract]

Quarterly Financial Information [Text Block]

SELECTED QUARTERLY FINANCIAL DATA - UNAUDITED



	Quarter Ended
	Mar. 31		Jun. 30		Sept. 30		Dec. 31
	(in thousands except per share data)
2019
Total revenue	$	330,932	$	312,282	$	307,471	$	315,523
Gross profit	$	135,303	$	103,869	$	118,552	$	114,140
Net income	$	30,998	$	22,833	$	26,563	$	20,641
Net income per share:
Basic	$	1.51	$	1.11	$	1.29	$	1.00
Diluted	$	1.44	$	1.06	$	1.24	$	0.96
2018
Total revenue	$	372,033	$	360,460	$	327,169	$	340,378
Gross profit	$	149,001	$	151,800	$	134,587	$	134,640
Net income (loss)	$	4,875	$	31,054	$	219	$	(7,355	)
Net income (loss) per share:
Basic	$	0.24	$	1.53	$	0.01	$	(0.36	)
Diluted	$	0.23	$	1.44	$	0.01	$	(0.36	)

______________________________________

Net loss for the quarter ended December 31, 2018 included the impact of $41.1 million in restructuring, strategic transaction and integration expenses. We also incurred an $8.6 million non-cash charge in the quarter ended December 31, 2018 associated

with a contract settlement that took place in the quarter ended March 31, 2018, which is included in contract settlement. Management of the Company concluded the contract settlement charge is not material to the three months ended December 31, 2018, or to any previously issued interim financial statements.

General and Summary of Significant Accounting Policies Intangible Assets #1 (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Cost	$ 263,275	$ 173,372
Accumulated Amortization	65,858	48,186
Finite-Lived Intangible Assets, Net	197,417	125,186
Intangible Assets, Gross (Excluding Goodwill)	277,266	181,607
INTANGIBLE ASSETS, net	$ 211,408	$ 133,421
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	10 years	10 years
Cost	$ 22,322	$ 19,399
Accumulated Amortization	13,519	12,147
Finite-Lived Intangible Assets, Net	$ 8,803	$ 7,252
Customer Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	12 years	9 years
Cost	$ 10,122	$ 5,319
Accumulated Amortization	5,506	5,272
Finite-Lived Intangible Assets, Net	$ 4,616	$ 47
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	9 years	9 years
Cost	$ 57,296	$ 57,916
Accumulated Amortization	19,787	13,363
Finite-Lived Intangible Assets, Net	$ 37,509	$ 44,553
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	4 years	4 years
Cost	$ 425	$ 425
Accumulated Amortization	425	425
Finite-Lived Intangible Assets, Net	$ 0	$ 0
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	15 years	15 years
Cost	$ 18,256	$ 7,456
Accumulated Amortization	2,254	1,618
Finite-Lived Intangible Assets, Net	$ 16,002	$ 5,838
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	13 years	11 years
Cost	$ 152,354	$ 82,857
Accumulated Amortization	24,228	15,361
Finite-Lived Intangible Assets, Net	$ 128,126	67,496
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	3 years
Cost	$ 2,500
Accumulated Amortization	139
Finite-Lived Intangible Assets, Net	2,361
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	$ 13,991	$ 8,235

General and Summary of Significant Accounting Policies Advertising Expenses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Advertising Expense	$ 0.1	$ 0.6	$ 0.2

Fair Value Measurement Fair Value Inputs, Liabilities, Hospira Quantitative Information (Details) - Hospira [Member]		12 Months Ended
	Feb. 03, 2017	Dec. 31, 2019	Dec. 31, 2018
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions, Expected Volatility Rate-Adjusted EBITDA	29.00%	30.00%	26.00%
Fair Value Assumptions, Market Price of Risk	6.93%	5.24%	5.99%
Fair Value Assumptions, Cost of Debt	4.16%	5.25%	4.08%
Measurement Input, Cost of Debt [Domain]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.1000	0.0825	0.0875
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0282	0.0287	0.0258

General and Summary of Significant Accounting Policies Post-retirement and Post-employment Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Pension and Other Postretirement Benefits Cost (Reversal of Cost)	$ 11.4	$ 11.4	$ 10.3

General and Summary of Significant Accounting Policies Property and Equipment #2 (Details)	12 Months Ended
	Dec. 31, 2019
Building [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	15
Building [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	30
Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	15
Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	30
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	15
Furniture, fixtures and molds [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2
Furniture, fixtures and molds [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5
Computer Equipment and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3
Computer Equipment and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5
Instruments Placed with Customers [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3
Instruments Placed with Customers [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	10

Acquisitions Hospira Text (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2017
Business Acquisition [Line Items]
Proceeds from Issuance of Debt		$ 75,000
Hospira [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		100.00%
Payments to Acquire Businesses, Gross		$ 260,000
Proceeds from Issuance of Debt		$ 75,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,200	3,200
contingent consideration gross	$ 225,000	$ 225,000

Revenue Disaggregation of Revenue by Geography (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenues	$ 315,523	$ 307,471	$ 312,282	$ 330,932	$ 340,378	$ 327,169	$ 360,460	$ 372,033	$ 1,266,208	$ 1,400,040	$ 1,292,613
EMEA [Member]
Disaggregation of Revenue [Line Items]
Revenues									130,530	134,363	119,934
Other foreign countries [Member]
Disaggregation of Revenue [Line Items]
Revenues									212,336	210,996	192,640
Foreign [Member]
Disaggregation of Revenue [Line Items]
Revenues									$ 342,866	$ 345,359	$ 312,574
UNITED STATES
Disaggregation of Revenue [Line Items]
Percent of total revenue									73.00%	75.00%	76.00%
Revenues									$ 923,342	$ 1,054,681	$ 980,039
International Sales [Domain]
Disaggregation of Revenue [Line Items]
Percent of total revenue									27.00%	25.00%	24.00%

Long-Term Obligations (Details) $ in Millions	12 Months Ended
Long-Term Obligations (Details) $ in Millions	Dec. 31, 2019 USD ($)
Long-Term Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity	$ 150.0
Line of Credit Facility, Remaining Borrowing Capacity	$ 150.0
Line of Credit Facility, Expiration Date	Nov. 08, 2022
Line of Credit Accordion	$ 100.0
Debt Issuance Costs, Line of Credit Arrangements, Gross	$ 1.4
Debt Instrument, Interest Rate Terms	In general, borrowing under the Credit Facility (other than Swingline loans) bears interest, at our option, based on the Base Rate plus applicable margin or the London Interbank Offered Rate ("LIBOR") rate plus applicable margin, as defined below:

Income Taxes:

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

INCOME TAXES

Income from continuing operations before taxes consisted of the following (in thousands):



	Year Ended December 31,
	2019		2018			2017
United States	$	32,849	$	(8,600	)	$	59,872
Foreign	81,858		30,974			(8,589		)
	$	114,707	$	22,374		$	51,283

The (benefit) provision for income taxes consisted of the following (in thousands):



	Year Ended December 31,
	2019			2018			2017
Current:
Federal	$	6,851		$	492		$	2,774
State	2,532			1,865			2,263
Foreign	7,994			9,136			3,170
	17,377			11,493			8,207
Deferred:
Federal	$	(6,720	)	$	(9,118	)	$	(20,878	)
State	(325		)	(3,072		)	(4,619		)
Foreign	3,340			(5,722		)	(71		)
	(3,705		)	(17,912		)	(25,568		)
	$	13,672		$	(6,419	)	$	(17,361	)

We have accrued for tax contingencies for potential tax assessments, and in 2019 we recognized a $4.2 million net increase, most of which related to various federal, state and foreign tax reserves.

On December 22, 2017, the Tax Act was enacted into legislation, which includes a broad range of provisions affecting businesses. The Tax Act significantly revises how companies compute their U.S. corporate tax liability by, among other provisions, reducing the corporate tax rate from 35% to 21% for tax years beginning after December 31, 2017, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the toll charge or transition tax.

Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 118, "Income Tax Accounting Implications of the Tax Cuts and Jobs Act" ("SAB 118"), a company selects between one of three scenarios to reflect the impact of the Tax Act in its financial statements within a measurement period. Those scenarios are (i) a final estimate which effectively closes the measurement period; (ii) a reasonable estimate leaving the measurement period open for future revisions; and (iii) no estimate as the law is still being analyzed in which case a company continues to apply its accounting on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. SAB 118 allows for the reporting provisional amounts for certain income tax effects in scenario (ii) and (iii). The measurement period begins in the reporting period that includes the Act’s enactment date and ends when an entity has obtained, prepared, and analyzed the information that was needed in order to complete the accounting requirements under ASC Topic 740. As of December 31, 2018, our accounting for the Tax Act was complete.

The toll charge on undistributed foreign earnings and profits (the “Transition Tax”) is a tax on certain untaxed accumulated and current earnings and profits ("E&P") of our foreign subsidiaries. We were able to reasonably estimate the Transition Tax and recorded a provisional Transition Tax expense of $2.0 million for the year ended December 31, 2017. On the basis of revised E&P computations that were completed during the reporting period, we recognized an additional measurement-period adjustment of $0.6 million to the Transition Tax obligation, with a corresponding adjustment of $0.6 million to income tax expense.

The revaluation of deferred taxes is an adjustment to future tax obligations as a result of the reduction of the corporate tax rate from 35% to 21%. We were able to reasonably estimate the effect of the revaluation of deferred taxes and recorded a provisional tax expense of $1.1 million for the year ended December 31, 2017. The computation of timing differences was completed during the reporting period. We recognized an additional measurement-period adjustment of $0.2 million, with a corresponding adjustment of $0.2 million to income tax expense.

A reconciliation of the provision for income taxes at the statutory rate to our effective tax rate is as follows (dollars in thousands):



	Year Ended December 31,
	2019					2018					2017
	Amount			Percent		Amount			Percent		Amount			Percent
Federal tax at the expected statutory rate	$	24,088		21.0	%	$	4,699		21.0	%	$	17,950		35.0	%
State income tax, net of federal effect	1,269			1.1	%	927			4.1	%	(403		)	(0.8	)%
Tax credits	(2,896		)	(2.5	)%	(4,961		)	(22.2	)%	(2,783		)	(5.4	)%
Global intangible low-taxed income	6,118			5.3	%	2,363			10.6	%	—			—	%
Foreign income tax differential	(5,939		)	(5.2	)%	(2,944		)	(13.2	)%	3,481			6.8	%
Stock based compensation	(8,446		)	(7.4	)%	(11,040		)	(49.3	)%	(18,958		)	(37.0	)%
Impact of the Tax Act	—			—	%	826			3.7	%	3,076			6.0	%
IP installment sale and repatriation	(2,118		)	(1.8	)%	3,252			14.5	%	3,367			6.6	%
Bargain purchase gain	—			—	%	—			—	%	(24,811		)	(48.4	)%
Section 162(m)	203			0.2	%	456			2.0	%	595			1.2	%
Other	1,393			1.2	%	3			0.1	%	1,125			2.2	%
	$	13,672		11.9	%	$	(6,419	)	(28.7	)%	$	(17,361	)	(33.8	)%

Tax credits in 2019, 2018 and 2017 consist principally of research and developmental tax credits.

The tax effect of the gain on bargain purchase is treated as a part of purchase accounting and is not a component of the income tax provision.

Certain intellectual property and assets were repatriated in 2019 from a liquidation of foreign subsidiaries to the U.S. parent. The tax effect of the repatriation is included as IP repatriation.

The components of our deferred income tax assets (liabilities) are as follows (in thousands):



	December 31,
	2019			2018
Deferred tax asset:
Accruals/other	2,632			11,109
Contingent consideration	—			12,451
Net operating loss carryforwards	—			12,686
Acquired future tax deductions	8,711			10,722
Stock-based compensation	9,654			10,775
Foreign currency translation adjustments	2,716			3,108
Tax credits	11,331			14,470
Inventory reserves	4,305			5,674
Allowance for doubtful accounts	4,242			830
Accrued restructuring	7,072			182
Chargebacks, discounts, customer concessions	20,975			—
Valuation allowance	(3,677		)	(5,436		)
	$	67,961		$	76,571
Deferred tax liability:
State income taxes	$	2,600		$	2,639
Foreign	997			612
Depreciation and amortization	23,839			35,387
Section 481(a) adjustment - change in accounting method	14,618			—
	$	42,054		$	38,638

Deferred tax asset, net	$	25,907		$	37,933

Tax Holidays and Carryforwards

Net operating loss ("NOL") carryforwards consist of: (a) federal NOL carryforwards of $14.8 million which will expire at various dates from 2020 to indefinite carryforward periods, (b) state NOL carryforwards of $1.4 million which will expire at various dates from 2029 to indefinite carryforward periods and (c) foreign NOL carryforwards of $18.4 million which will expire at various dates from 2020 to indefinite carryforward periods. Under Section 382 of the Internal Revenue Code, certain ownership changes limit the utilization of the NOL carryforwards, and the amount of federal NOL carryforwards recorded is the net federal benefit available.

Other carryforwards include state research and development (“R&D”) tax credit carryforwards of $14.7 million, which have an indefinite carryforward period.

A substantial portion of our manufacturing operations in Costa Rica operate under various tax holiday and tax incentive programs due to expire in whole or in part in 2027. Certain of the holidays may be extended if specific conditions are met. The net impact of these tax holiday and tax incentives was an increase to our net earnings by $7.8 million or $0.36 per diluted share in 2019 and by $8.8 million or $0.41 per diluted share in 2018.

Foreign currency translation adjustments, and related tax effects, are an element of “other comprehensive income” and are not included in net income other than the revaluation of the associated deferred tax asset due to the Tax Act.

As of December 31, 2019, we have estimated $78.5 million of undistributed foreign earnings and profits. Such earnings were previously subject to U.S. tax as a result of the Tax Act and much of any future remittances would generally be subject to no U.S. tax as a result of dividends received deductions and/or foreign tax credit relief. We intend to invest

substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, indefinitely outside of the U.S. in those jurisdictions in which we incur significant additional costs upon repatriation of such amounts.

We are subject to taxation in the United States and various states and foreign jurisdictions. Our United States federal income tax returns for tax years 2016 and forward are subject to examination by the Internal Revenue Service. Our principal state income tax returns for tax years 2012 and forward are subject to examination by the state tax authorities. The total gross amount of unrecognized tax benefits as of December 31, 2019 was $15.0 million which, if recognized, would impact the effective tax rate. We believe that adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax examinations cannot be predicted with certainty. As of December 31, 2019, it is not possible to estimate the amount of change, if any, in the unrecognized tax benefits that is reasonably possible within the next twelve months. We recognize accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. We have not accrued any penalties or interest as of December 31, 2019 or December 31, 2018.

The following table summarizes our cumulative gross unrecognized tax benefits (in thousands):



	Year Ended December 31,
	2019			2018			2017
Beginning balance	$	10,824		$	6,527		$	2,000
Increases to prior year tax positions	138			—			77
Increases due to acquisitions	—			—			640
Increases to current year tax positions	4,231			4,536			3,992
Decreases to prior year tax positions	(3		)	(146		)	(12		)
Decrease related to lapse of statute of limitations	(163		)	(93		)	(170		)
Ending balance	$	15,027		$	10,824		$	6,527

Share Based Award Stock Options Granted and Valuation (Details) - Time-based stock option [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	6,265	5,815	8,825
Time based options grant date fair value	$ 424	$ 425	$ 375
Expected term (years)	5 years 6 months	5 years 6 months	5 years 6 months
Expected stock price volatility	28.00%	24.00%	27.00%
Risk-Free Interest Rate	2.20%	2.30%	1.10%
Expected Dividend Yield	0.00%	0.00%	0.00%
Weighted Average Exercise Price	$ 225.27	$ 269.80	$ 158.20
Weighted Average Grant Date Fair Value per option	$ 67.73	$ 73.14	$ 42.51

Income Taxes Operating Loss Carryforwards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating loss carryforwards [Abstract]
Share-based Payment Arrangement, Exercise of Option, Tax Benefit	$ 9,653	$ 12,617	$ 20,004
UNITED STATES
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	14,800
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	1,400
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 18,400

Income Taxes Provision for income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Share-based Payment Arrangement, Exercise of Option, Tax Benefit	$ 9,653	$ 12,617	$ 20,004
Current Federal Tax Expense (Benefit)	6,851	492	2,774
Current State and Local Tax Expense (Benefit)	2,532	1,865	2,263
Current Foreign Tax Expense (Benefit)	7,994	9,136	3,170
Current Income Tax Expense (Benefit)	17,377	11,493	8,207
Deferred Federal Income Tax Expense (Benefit)	(6,720)	(9,118)	(20,878)
Deferred State and Local Income Tax Expense (Benefit)	(325)	(3,072)	(4,619)
Deferred Foreign Income Tax Expense (Benefit)	3,340	(5,722)	(71)
Deferred Income Tax Expense (Benefit)	(3,705)	(17,912)	(25,568)
PROVISION FOR INCOME TAXES	$ 13,672	$ (6,419)	$ (17,361)

Selected Quarterly Financial Data - Unaudited (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 315,523	$ 307,471	$ 312,282	$ 330,932	$ 340,378	$ 327,169	$ 360,460	$ 372,033	$ 1,266,208	$ 1,400,040	$ 1,292,613
Gross Profit	114,140	118,552	103,869	135,303	134,640	134,587	151,800	149,001	471,864	570,028	426,095
Net Income	$ 20,641	$ 26,563	$ 22,833	$ 30,998	$ (7,355)	$ 219	$ 31,054	$ 4,875	$ 101,035	$ 28,793	$ 68,644
Basic	$ 1.00	$ 1.29	$ 1.11	$ 1.51	$ (0.36)	$ 0.01	$ 1.53	$ 0.24	$ 4.90	$ 1.41	$ 3.50
Diluted	$ 0.96	$ 1.24	$ 1.06	$ 1.44	$ (0.36)	$ 0.01	$ 1.44	$ 0.23	$ 4.69	$ 1.33	$ 3.29
Restructuring, strategic transaction and integration expenses					$ 41,100				$ 80,574	$ 105,390	$ 77,967
Contractsettlements					$ 8,600				$ 5,737	$ 41,613	$ 0

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

General and Summary of Significant Accounting Policies Property and Equipment #3 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Depreciation	$ 59.3	$ 58.1	$ 51.6

Share Based Award Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restricted Stock and Performance Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested and expected to vest	340,704
Shares granted	99,513
Change in units due to performance expectations	(14,444)
Vested	(185,662)
Forfeited	(7,584)
Nonvested and expected to vest	232,527	340,704
Nonvested, Weighted Average Grant Date Fair Value	$ 205.82	$ 155.27
Grants in period, Grant date fair value per share	229.01
Change in units due to performance expectations	238.03
Vested Intrinsic Value, Amount Per Share	122.55
Forfeited, Weighted Average Grant Date Fair Value	$ 216.29
Remaining Contractual Terms	8 months 12 days
Aggregate intrinsic value	$ 43,510
Performance Restricted Stock Units (PRSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	37,657	30,348	20,686
Grants in period, Grant date fair value per share	$ 231.63	$ 248.65	$ 154.75
Grant date fair value performance restricted stock units	$ 8,723	$ 7,546	$ 3,201
Intrinsic value vested	$ 26,445	$ 0	$ 0
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Shares Earned	114,032	0	0
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	61,856	63,094	107,678
Grants in period, Grant date fair value per share	$ 227.42	$ 252.42	$ 156.49
Grant date fair value of restricted stock units granted	$ 14,067	$ 15,926	$ 16,851
Intrinsic value vested	$ 16,753	$ 17,086	$ 9,813

Fair Value Measurement (Details) - USD ($) $ in Thousands	12 Months Ended
Fair Value Measurement (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent Earn-out Liability	$ 17,300	$ 47,400	$ 27,000	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances	17,300	0	19,000
Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)	$ (47,400)	$ 20,400	$ 8,000

Derivatives and Hedging Activities (Notes)

12 Months Ended

Dec. 31, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

DERIVATIVES AND HEDGING ACTIVITIES

Hedge Accounting and Hedging Program

The purpose of our cash flow hedging program is to manage the foreign currency exchange rate risk on forecasted expenses denominated in currencies other than the functional currency of the operating unit. We do not issue derivatives for trading or speculative purposes.

In May 2017, we entered into a two-year cross-currency par forward contract to hedge a portion of our Mexico forecasted expenses denominated in Pesos ("MXN"). To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The par forward contract is designated and qualifies as a cash flow hedge. Our derivative instrument is recorded at fair value on the Consolidated Balance Sheets and is classified based on the instrument's maturity date. We record changes in the fair value of the effective portion of the derivative instrument as a component of Other Comprehensive Income (Loss) and we reclassify that gain or loss into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. The term of this currency forward contract was May 1, 2017 to May 1, 2019. The derivative instrument had a fixed forward rate of 20.01MXN/USD over the term of the two-year contract.

In January 2018, we entered into an additional six-month cross-currency par forward contract that extended our previous hedge of a portion of our Mexico forecasted expenses denominated in MXN. The term of this six-month contract was May 1, 2019 to November 1, 2019. The derivative instrument had a fixed forward rate of 20.43 MXN/USD over the term of the six-month contract.

In November 2018, we entered into a one-year cross-currency par forward contract again extending the hedge of a portion of our Mexico forecasted expenses denominated in MXN. The total notional amount of this outstanding derivative as of December 31, 2019 was approximately 364.8 million MXN. The term of the one-year hedge is November 1, 2019 to November 3, 2020. The derivative instrument matures in equal monthly amounts at a fixed forward rate of 22.109 MXN/USD.

The following table presents the fair values of our derivative instruments included within the Consolidated Balance Sheets (in thousands):



	Derivatives
		December 31,
	Consolidated Balance Sheet Location	2019		2018
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:	Prepaid expenses and other current assets	$	2,366	$	187
	Other assets	—		545
Total derivatives designated as cash flow hedging instruments		$	2,366	$	732

The following table presents the amounts affecting the Consolidated Statements of Operations (in thousands):



		Year Ended December 31,
	Line Item in the Consolidated Statements of Operations	2019		2018		2017
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	916	$	743	$	885

We recognized the following gains on our foreign exchange contract designated as a cash flow hedge (in thousands):



	Amount of Gain Recognized in Other Comprehensive Income on Derivatives						Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Year Ended December 31,							Year Ended December 31,
	2019		2018		2017		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2019		2018		2017
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	2,550	$	2,063	$	296	Cost of goods sold	$	916	$	743	$	885
Total derivatives designated as cash flow hedging instruments	$	2,550	$	2,063	$	296		$	916	$	743	$	885

As of December 31, 2019, we expect approximately $2.4 million of the deferred gain on the outstanding derivatives in accumulated other comprehensive income to be reclassified to net income during the next 12 months concurrent with the underlying hedged transactions also being reported in net income.

Share Based Award ESPP Narrative (Details)	Dec. 31, 2019 shares
Share-based Payment Arrangement [Abstract]
ESPP Original Issuance	750,000
ESPP Annual Issuance Increase Limit	300,000
Shares available in employee stock purchase plan	133,487

Share Based Award Stock Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Stock compensation	$ 21,918	$ 24,241	$ 19,352
Tax benefit from stock-based compensation cost	4,840	5,706	7,247
Indirect tax benefit	680	$ 2,199	$ 1,374
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 23,600
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	9 months 18 days

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	COMMITMENTS AND CONTINGENCIES Legal Proceedings Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Pfizer, Inc. subsidiaries, Hospira, Inc., Hospira Worldwide, Inc. and certain other defendants relating to the intravenous saline solutions part of the HIS business. Plaintiffs seek to represent classes consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants’ allegedly unlawful conduct ceases. Plaintiffs allege that U.S. manufacturer defendants conspired together to restrict output and artificially fix, raise, maintain and/or stabilize the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. On July 5, 2018, the District Court granted defendants’ motion to dismiss the operative complaint for failing to state a valid antitrust claim, but allowed the plaintiffs to file a second amended complaint. On September 6, 2018, plaintiffs filed a second amended complaint adding new allegations in support of their conspiracy claims and adding ICU as a defendant. All defendants have filed a motion to dismiss this second amended complaint. Briefing is complete and we are awaiting the Court's ruling. On February 3, 2017, we completed the acquisition of the HIS business from Pfizer. This litigation is the subject of a claim for indemnification against us by Pfizer and a cross-claim for indemnification against Pfizer by us under the HIS stock and asset purchase agreement. In addition, in August 2015, the New York Attorney General issued a subpoena to Hospira, Inc. requesting that the company provide information regarding certain business practices in the intravenous solutions part of the HIS business. Separately, in April 2017, we received a grand jury subpoena issued by the United States District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoenas call for production of documents related to the manufacturing, selling, pricing and shortages of intravenous solutions, including saline, as well as communications among market participants regarding these issues. On December 10, 2018, we were informed by the U.S. Department of Justice, Antitrust Division, that their investigation has been closed. In April 2018, the U.S. Department of Justice issued a HIPAA subpoena to Hospira, Inc., requesting production of documents and records regarding the manufacturing, production, testing, quality and validation of the Sapphire™ infusion pumps, sets and related accessories distributed by the company. We have coordinated with Pfizer to produce the requested records to the Department of Justice. In March 2018, a dispute with a product partner resulted in a redefinition of our contractual arrangement and in the rights and remedies determined under such arrangement. In March 2018, the resolution of the dispute resulted in a $28.9 million net charge to the consolidated statement of operations. In addition, during the fourth quarter of 2018, we incurred $12.7 million in additional contract settlement charges related to this arrangement as a result of the write-off of assets and additional expenses associated with the restructuring of products. From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business. Our management does not believe that the resolution of the unsettled legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations. Off Balance Sheet Arrangements In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. We have never incurred, nor do we expect to incur, any liability for indemnification. Contingencies We had a contractual earn-out arrangement in connection with our acquisition of the HIS business that ended on December 31, 2019, whereby Pfizer was entitled up to an additional $225 million in cash upon achievement of performance targets for the company for the three years ending December 31, 2019. We did not meet the performance targets required for payout of this earn-out. During November 2019, we acquired Pursuit (see Note 2, Acquisitions). Total consideration for the acquisition includes a potential contractual earn-out of up to $50.0 million calculated based upon the achievement of certain performance targets during the earn-out period.

Derivatives and Hedging Activities Derivative Balance Sheet Location (Details) - Foreign Exchange Forward [Member] - Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Prepaid Expenses and Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 2,366	$ 187
Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	0	545
Derivative Financial Instruments, Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	$ 2,366	$ 732

Fair Value Measurement (Notes)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

FAIR VALUE MEASUREMENTS

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:


•	Level 1: quoted prices in active markets for identical assets or liabilities;

•

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or


•	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.

In 2017, we recognized an earn-out liability upon the acquisition of HIS from Pfizer. Pfizer was entitled up to $225 million in cash if certain performance targets for the combined company for the three years ending December 31, 2019 were achieved. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model included other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. The initial value assigned to the contingent consideration was a result of forecasted product demand of our HIS business, as discussed further in Note 2: Acquisitions. At each reporting date subsequent to the acquisition we remeasured the earn-out using the same methodology above and recognize any changes in value. As of December 31, 2019, it was determined that we did not meet the necessary performance targets that would require payout of any of the HIS earn-out liability.

In the fourth quarter of 2019, we recognized an earn-out liability related to the acquisition of Pursuit (see Note 2, Acquisitions). Pursuit's equity holders are potentially entitled up to $50.0 million in additional cash consideration contingent upon the achievement of certain sales and gross profit targets for specific customers.The earn-out paid will be calculated as a percentage of gross profit achieved during the earn-out period against a pre-determined target gross profit, not to exceed $50.0 million. We used a Monte Carlo simulation model to determine the fair value of the earn-out. The Monte Carlo simulation model utilizes multiple input variables to determine the value of the earn-out including historical volatility, a risk free interest rate, counter party credit risk and projected future gross profit, see below simulation input table related to Pursuit. The historical volatility was based on the median of ICU and a certain peer group. The risk-free interest rate is equal to the yield, as of the valuation date, of the zero-coupon U.S. Treasury bill that is commensurate with the term of the earn-out. The counter party credit risk is based on a synthetic credit rating of B1. If the probabilities in the model significantly change from what we initially and subsequently anticipate, the change could have a significant impact on our financial statements in the period recognized. Our contingent earn-out liability is separately stated in our consolidated balance sheets.

The following table provides a reconciliation of our Level 3 earn-out liabilities measured at estimated fair value based on an initial valuation and updated quarterly for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	Earn-out Liability
Contingent earn-out liability, January 1, 2017	$	—
Acquisition date fair value estimate of earn-out	19,000
Change in fair value of contingent earn-out (included in income from operations as a separate line item)	8,000
Contingent earn-out liability, December 31, 2017	$	27,000
Acquisition date fair value estimate of earn-out	—
Change in fair value of contingent earn-out (included in income from operations as a separate line item)	20,400
Contingent earn-out liability, December 31, 2018	47,400
Acquisition date fair value estimate of earn-out⁽¹⁾	17,300
Change in fair value of contingent earn-out (included in income from operations as a separate line item)	(47,400		)
Contingent earn-out liability, December 31, 2019	$	17,300

_________________________

⁽¹⁾Relates to our acquisition of Pursuit, (see Note 2, Acquisitions).

Changes in the fair value of the HIS earn-out subsequent to the fair value calculated at acquisition are due to a change in the forecast of the underlying target, adjusted EBITDA, and due to changes in other assumptions used in the Monte Carlo simulation, as detailed in the below table.

The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities as of the acquisition date to December 31, 2019. Significant increases or decreases in these inputs in isolation could result in a significant impact on our fair value measurement.

HIS Earn-out



Simulation Input	As of December 31, 2018		As of December 31, 2017		At Acquisition February 3, 2017
Adjusted EBITDA Volatility	30.00	%	26.00	%	29.00	%
WACC	8.25	%	8.75	%	10.00	%
20-year risk free rate	2.87	%	2.58	%	2.82	%
Market price of risk	5.24	%	5.99	%	6.93	%
Cost of debt	5.25	%	4.08	%	4.16	%

Pursuit Earn-out



Simulation Input	As of December 31, 2019		At Acquisition November 2, 2019
Revenue/Gross Profit Volatility	20.00	%	20.00	%
Discount Rate	15.00	%	15.00	%
Risk free rate	1.55	%	1.55	%
Counter Party Risk	6.00	%	6.00	%

The fair value of our investments, which consists of corporate bonds, is estimated using observable market based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs.

The fair value of our Level 2 forward currency contract is estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative.

There were no transfers between levels in 2019 or 2018.

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at December 31, 2019
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale debt securities:
Short-term	$	23,967	$	—	$	23,967	$	—
Foreign exchange forwards:
Prepaid expenses and other current assets	2,366		—		2,366		—
Total Assets	$	26,333	$	—	$	26,333	$	—

Liabilities:

Earn-out liability	$	17,300	$	—	$	—	$	17,300
Total Liabilities	$	17,300	$	—	$	—	$	17,300



	Fair value measurements at December 31, 2018
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale debt securities:
Short-term	$	37,329	$	—	$	37,329	$	—
Long-term	2,025		—		2,025		—
Foreign exchange forwards:
Prepaid expenses and other current assets	187		$	—	$	187	$	—
Other assets	545		$	—	$	545	$	—
Total Assets	$	39,354	$	—	$	39,354	$	—

Liabilities:

Earn-out liability	$	47,400	$	—	$	—	$	47,400
Total Liabilities	$	47,400	$	—	$	—	$	47,400

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Leases Lease Cost (Details) $ in Thousands	12 Months Ended
Leases Lease Cost (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating Lease, Cost	$ 10,011
Short-term Lease, Cost	322
Lease, Cost	$ 10,333

Income Taxes Tax Reform (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes Tax Reform (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	35.00%
RepatriationTollCharge	$ 600	$ 2,000
Transitiontaxadjustment	600
IncomeTaxExpenseDeferredTaxAccountRevaluation	200	1,100
Taxreformdeferredtaxrevaluationadjustment	200
GILTItaxexpense	$ 6,118	$ 2,363	$ 0

General and Summary of Significant Accounting Policies Foreign Currency (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Foreign Currency [Abstract]
Foreign Currency Transaction Gain (Loss), Realized	$ (0.7)	$ 7.9	$ 1.8

Long-Term Obligations (Tables)

12 Months Ended

Dec. 31, 2019

Long-Term Debt Disclosure [Abstract]

Interest Margin and Commitment Fee [Table Text Block]

The applicable interest margins and the commitment fee with respect to the Credit Facility shall be based on the Total Leverage Ratio pursuant to the following pricing grid:



Level	Consolidated Total Leverage Ratio	Commitment Fee	LIBOR +	Base Rate +
I	Less than 1.00 to 1.00	0.15%	1.25%	0.25%
II	Greater than or equal to 1.00 to 1.00 but less than 2.00 to 1.00	0.20%	1.50%	0.50%
III	Greater than or equal to 2.00 to 1.00 but less than 2.50 to 1.00	0.25%	1.75%	0.75%
IV	Greater than or equal to 2.50 to 1.00	0.30%	2.00%	1.00%

Accrued Liabilities an Other Long-term Liabilities Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Other Long-term Liabilities [Abstract]
Operating lease liabilities, LT	$ 28,896	$ 0
Contract liabilities	472	14,020
Deferred Revenue	94	468
Benefits	1,131	962
Accrued rent	1,642	1,779
Contract settlement	0	1,667
Other	585	1,696
OTHER LONG-TERM LIABILITIES	$ 32,820	$ 20,592

Share Based Award (Tables)

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Schedule of stock compensation and related tax benefits [Table Text Block]

The table below summarizes compensation costs and related tax benefits (in thousands):



	Year ended December 31,
(In thousands)	2019		2018		2017
Stock compensation expense	$	21,918	$	24,241	$	19,352
Tax benefit from stock-based compensation cost	$	4,840	$	5,706	$	7,247
Indirect tax benefit	$	680	$	2,199	$	1,374

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The table below summarizes the total time-based stock options granted, total valuation and the weighted average assumptions (dollars in thousands, except per option amounts):



	Year ended December 31,
	2019			2018			2017
Number of time-based options granted	6,265			5,815			8,825
Grant date fair value of options granted (in thousands)	$	424		$	425		$	375
Weighted average assumptions for stock option valuation:
Expected term (years)	5.5			5.5			5.5
Expected stock price volatility	28.0		%	24.0		%	27.0		%
Risk-free interest rate	2.2		%	2.3		%	1.1		%
Expected dividend yield	—		%	—		%	—		%
Weighted average grant price per option	$	225.27		$	269.80		$	158.20
Weighted average grant date fair value per option	$	67.73		$	73.14		$	42.51

Share-based Payment Arrangement, Option, Activity [Table Text Block]

A summary of our stock option activity as of and for the year ended December 31, 2019 is as follows:



	Shares		Weighted Average Exercise Price Per Share		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018	1,186,928		$	63.66
Granted	6,265		$	225.27
Exercised	(145,339	)	$	53.18
Forfeited or expired	—		$	—
Outstanding at December 31, 2019	1,047,854		$	66.08	4.1	$	127,556
Exercisable at December 31, 2019	1,041,589		$	65.12	4.0	$	127,556
Vested and expected to vest, December 31, 2019	1,047,854		$	66.08	4.1	$	127,556

Exercised Options Data [Table Text Block]

The following table presents information regarding stock option activity:



	Year ended December 31,
(In thousands)	2019		2018		2017
Intrinsic value of options exercised	$	22,976	$	51,105	$	71,283
Cash received from exercise of stock options	$	7,732	$	14,275	$	32,003
Tax benefit from stock option exercises	$	9,653	$	12,617	$	20,004

Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

The table below summarizes our restricted stock award activity (dollars in thousands):



	Year ended December 31,
(In thousands except shares and per share amounts)	2019		2018		2017
PRSU
Shares granted	37,657		30,348		20,686
Shares earned	114,032		—		—
Grant date fair value per share	$	231.63	$	248.65	$	154.75
Grant date fair value	$	8,723	$	7,546	$	3,201
Intrinsic value vested	$	26,445	$	—	$	—

RSU
Shares granted	61,856		63,094		107,678
Grant date fair value per share	$	227.42	$	252.42	$	156.49
Grant date fair value	$	14,067	$	15,926	$	16,851
Intrinsic value vested	$	16,753	$	17,086	$	9,813

Nonvested Restricted Stock Shares Activity [Table Text Block]

The table below provides a summary of our PRSU and RSU activity as of and for the year ended December 31, 2019:



	Number of Units		Grant Date Fair Value Per Share		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value
Non-vested at December 31, 2018	340,704		$	155.27
Change in units due to performance expectations^(a)	(14,444	)	$	238.03
Granted	99,513		$	229.01
Vested	(185,662	)	$	122.55
Forfeited	(7,584	)	$	216.29
Non-vested and expected to vest at December 31, 2019	232,527		$	205.82	0.7	$	43,510

Schedule of employee stock purchase plan (ESPP) [Table Text Block]

The table below summarizes the number and intrinsic value of ESPP share purchases and the weighted average valuation assumptions for the 2017 purchase period.




	2017
ESPP shares purchased by employees	23,426
Intrinsic value of ESPP purchases (in thousands)	$	986
Weighted average assumptions for ESPP valuation:
Expected term (in years)	0.5
Expected stock price volatility	28.1		%
Risk-free interest rate	0.6		%
Expected dividend yield	—		%

Long-Term Obligations Line of Credit Pricing (Details)	12 Months Ended
Long-Term Obligations Line of Credit Pricing (Details)	Dec. 31, 2019
Pricing Level I [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.15%
LIBOR Basis Spread on Variable Rate	1.25%
Debt Instrument, Basis Spread on Variable Rate	0.25%
Pricing Level II [Member] [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.20%
LIBOR Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Spread on Variable Rate	0.50%
Pricing Level III [Member] [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.25%
LIBOR Basis Spread on Variable Rate	1.75%
Debt Instrument, Basis Spread on Variable Rate	0.75%
Pricing Level IV [Member] [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.30%
LIBOR Basis Spread on Variable Rate	2.00%
Debt Instrument, Basis Spread on Variable Rate	1.00%

Share Based Award Stock Option Activity (Details) - Share-based Payment Arrangement, Option [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, Outstanding, Number \| shares	1,186,928
Granted \| shares	6,265
Exercised \| shares	(145,339)
Forfeited or expired \| shares	0
Options, Outstanding, Number \| shares	1,047,854
Exercisable \| shares	1,041,589
Vested and Expected to Vest \| shares	1,047,854
Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 63.66
Weighted Average Exercise Price \| $ / shares	225.27
Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	53.18
Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value \| $ / shares	0
Options, Outstanding, Weighted Average Exercise Price \| $ / shares	66.08
Exercise Price Range, Exercisable Options, Weighted Average Exercise Price \| $ / shares	65.12
Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 66.08
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years 1 month 6 days
Options, Exercisable, Weighted Average Remaining Contractual Term	4 years
Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years 1 month 6 days
Options, Outstanding, Intrinsic Value \| $	$ 127,556
Options, Exercisable, Intrinsic Value \| $	127,556
Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 127,556

Accrued Liabilities an Other Long-term Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities [Abstract]
Salaries and benefits	$ 21,116	$ 20,538
Incentive compensation	15,221	42,913
Accruedsupplychainrestructuring	23,119	0
Operating Lease, Liability, Current	7,362	0
Accrued Professional Fees	4,782	15,996
Accrued Product Field Action.	2,096	5,316
Consigned inventory	0	1,118
Third-party Inventory	0	1,089
Legal accrual	826	1,400
Accrued sales taxes	2,615	2,941
Warranties and returns	782	1,124
Deferred revenue	4,761	3,814
Accrued other taxes	4,054	3,213
Outside commissions	3,942	3,977
Accrued freight	11,238	10,953
Restructuring accrual	5,459	1,046
UnfavorablecontractliabilityST	1,935	0
Contract settlement	1,667	2,083
Accrued research and development expense	0	1,451
Other	6,801	9,848
Accrued liabilities	$ 117,776	$ 128,820

Prepaids and Other Current Assets Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Prepaid Expense and Other Assets, Current [Abstract]
Deposit Assets	$ 1,375	$ 1,087
Other Prepaid Expense, Current	13,778	12,476
Other Receivables	0	20,137
Deferred Costs and Other Assets	3,332	1,951
Prepaid insurance and property taxes	5,450	2,666
Prepaid other taxes	4,422	5,072
Deferred tax charge	1,266	1,180
Other Assets, Current	4,358	1,548
Prepaid expenses and other current assets	$ 33,981	$ 46,117

Geographic Information and Significant Customers Geographic Information (Tables)

12 Months Ended

Dec. 31, 2019

Geographic Areas, Long-Lived Assets [Abstract]

Long-lived Assets by Geographic Areas [Table Text Block]

The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):



	As of December 31,
	2019		2018
Costa Rica	$	96,442	$	81,920
Mexico	69,141		64,242
Other LATAM	31,905		22,828
Canada	4,769		4,545
Italy	7,921		7,819
Spain	6,411		6,516
Other Europe	3,135		2,427
APAC	17,200		15,152
Total Foreign	$	236,924	$	205,449
United States	539,316		489,415
Worldwide Total	$	776,240	$	694,864

Document and Entity Information Document - USD ($)	12 Months Ended
Document and Entity Information Document - USD ($)	Dec. 31, 2019	Jan. 31, 2020	Jun. 28, 2019
Cover page.
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	001-34634
Entity Registrant Name	ICU MEDICAL INC/DE
Entity Central Index Key	0000883984
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0022692
Entity Address, Address Line One	951 Calle Amanecer
Entity Address, City or Town	San Clemente
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92673
City Area Code	949
Local Phone Number	366-2183
Title of 12(b) Security	Common stock, par value $0.10 per share
Trading Symbol	ICUI
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 4,836,397,922
Entity Common Stock, Shares Outstanding		20,774,907
Documents Incorporated by Reference	Portions of the Proxy Statement for registrant’s 2020 Annual Meeting of Stockholders filed or to be filed pursuant to Regulation 14A within 120 days following registrant’s fiscal year ended December 31, 2019, are incorporated by reference into Part III of this Report.

Leases Supplemental Cash Flow Lease Information (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Cash Flow, Supplemental Disclosures [Text Block]

The following table presents the supplemental cash flow information related to our leases (in thousands):



	For the year ended December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	10,344

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	3,230

Stockholders' Equity

12 Months Ended

Dec. 31, 2019

Stockholders' Equity Attributable to Parent [Abstract]

Treasury Stock [Text Block]

Treasury Stock

In August 2019, our Board of Directors approved a common stock purchase plan to purchase up to $100.0 million of our common stock. This plan replaced our prior plan and has no expiration date. We have $100.0 million remaining on this purchase plan. We did not purchase any of our common stock under our common stock purchase plan in 2019, 2018 or 2017. We are currently limited on share purchases in accordance with the terms and conditions of our Credit Facility, (see Note 11, Long-Term Obligations).

In 2019, we withheld 80,186 shares of our common stock from employee vested restricted stock units in consideration for $18.6 million in payments for the employee's share award income tax withholding obligations. We had 850 shares remaining in treasury at December 31, 2019.

In 2018, we withheld 26,307 shares of our common stock from employee vested restricted stock units in consideration for $6.3 million in payments for the employee's share award income tax withholding obligations. We have 408 shares remaining in treasury at December 31, 2018.

In 2017, we withheld 27,636 shares of our common stock from employee vested restricted stock units in consideration for $4.1 million in payments for the employee's share award income tax withholding obligations. We had no shares remaining in treasury at December 31, 2017.

We use treasury stock to issue shares for stock option exercises, restricted stock grants.

Accumulated Other Comprehensive (Loss) Income ("AOCI")

The components of AOCI, net of tax, were as follows (in thousands):



	Foreign Currency Translation Adjustments			Unrealized Gains on Cash Flow Hedges			Other Adjustments			Total
Balance as of January 1, 2017	$	(21,272	)	$	—		$	—		$	(21,272	)
Other comprehensive income (loss) before reclassifications	6,694			184			(16		)	6,862
Amounts reclassified from AOCI	—			(549		)	—			(549		)
Other comprehensive income (loss)	6,694			(365		)	(16		)	6,313
Balance as of December 31, 2017	(14,578		)	(365		)	(16		)	(14,959		)
Other comprehensive (loss) income before reclassifications	(3,104		)	1,568			115			(1,421		)
Amounts reclassified from AOCI	—			(565		)	—			(565		)
Other comprehensive (loss) income	(3,104		)	1,003			115			(1,986		)
Balance as of December 31, 2018	$	(17,682	)	$	638		$	99		$	(16,945	)
Other comprehensive income (loss) before reclassifications	372			1,938			(71		)	2,239
Amounts reclassified from AOCI	—			(696		)	—			(696		)
Other comprehensive income (loss)	372			1,242			(71		)	1,543
Balance as of December 31, 2019	$	(17,310	)	$	1,880		$	28		$	(15,402	)

Stockholders' Equity Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (16,945)	$ (14,959)	$ (21,272)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	2,239	(1,421)	6,862
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(696)	(565)	(549)
Other Comprehensive Income (Loss), Net of Tax	1,543	(1,986)	6,313
Accumulated Other Comprehensive Income (Loss), Net of Tax	(15,402)	(16,945)	(14,959)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	(17,682)	(14,578)	(21,272)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	372	(3,104)	6,694
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0	0
Other Comprehensive Income (Loss), Net of Tax	372	(3,104)	6,694
Accumulated Other Comprehensive Income (Loss), Net of Tax	(17,310)	(17,682)	(14,578)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	638	(365)	0
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	1,938	1,568	184
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax	(696)	(565)	(549)
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent	1,242	1,003	(365)
Accumulated Other Comprehensive Income (Loss), Net of Tax	1,880	638	(365)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	99	(16)	0
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(71)	115	(16)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0	0
Other Comprehensive Income (Loss), Net of Tax	(71)	115	(16)
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ 28	$ 99	$ (16)

Leases Supplemental Cash Flow Lease Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating Lease, Payments	$ 10,344
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 3,230

Prepaids and Other Current Assets Related Party Details (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
CommonSharesSoldbyPfizer	2,500
Payments for Other Fees	$ 8.0
Pfizer MSA Product Costs	78.2	$ 72.4
ICU Medical MSA Revenue	$ 81.0	$ 70.2
Hospira [Member]
Related Party Transaction [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,200		3,200

Income Taxes Tax Carryforwards (Details) $ in Millions	Dec. 31, 2019 USD ($)
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount	$ 14.7

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
REVENUES:
TOTAL REVENUE	$ 1,266,208	$ 1,400,040	$ 1,292,613
Cost of Goods Sold	794,344	830,012	866,518
Gross profit	471,864	570,028	426,095
OPERATING EXPENSES:
Selling, general and administrative	276,982	320,002	302,169
Research and development	48,611	52,867	51,253
Restructuring, strategic transaction and integration expenses	80,574	105,390	77,967
Change in fair value of contingent earn-out	(47,400)	20,400	8,000
Contractsettlements	5,737	41,613	0
Impairment of assets held for sale			0
Total operating expenses	364,504	540,272	439,389
Income (Loss) from operations	107,360	29,756	(13,294)
Bargain Purchase Gain	0	0	(70,890)
Interest Expense	(549)	(709)	(2,047)
OTHER INCOME (EXPENSE),NET	7,896	(6,673)	(4,266)
Income before income taxes	114,707	22,374	51,283
(PROVISION) BENEFIT FOR INCOME TAXES	(13,672)	6,419	17,361
Net Income	$ 101,035	$ 28,793	$ 68,644
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Basic	$ 4.90	$ 1.41	$ 3.50
Diluted	$ 4.69	$ 1.33	$ 3.29
WEIGHTED AVERAGE NUMBER OF SHARES
Basic (in shares)	20,629	20,394	19,614
Diluted (in shares)	21,545	21,601	20,858
Product [Member]
REVENUES:
Net sales	$ 1,266,208	$ 1,400,040	$ 1,292,166
Product and Service, Other [Member]
REVENUES:
Net sales	$ 0	$ 0	$ 447

Stockholders' Equity (Details) - USD ($) $ in Millions	12 Months Ended
Stockholders' Equity (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Equity, Class of Treasury Stock [Line Items]
Treasury stock purchase plan	$ 100.0
Treasury stock purchase plan remaining available	$ 100.0
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation	80,186	26,307	27,636
Payment, Tax Withholding, Share-based Payment Arrangement	$ 18.6	$ 6.3	$ 4.1
Treasury Stock, Common, Shares	850	408	0

General and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Preparation

The consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. These consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These reclassifications had no impact on net income, stockholders' equity or cash flows as previously reported. For the years ended December 31, 2018 and 2017, we reported foreign exchange gains and losses in other income (expense), net, and removed them from selling, general and administrative expenses. We reclassified related-party receivables to prepaid expenses and other current assets for the current year's presentation, as Pfizer, Inc. ("Pfizer") had sold all of its shares of our ICU common stock as of December 31, 2018, thereby ending its related-party relationship with us. For the year ended December 31, 2018, we reclassified operating cash flows due to the purchase and usage of spare parts. The operating cash flows due to the usage of spare parts are included as an adjustment to reconcile net income to net cash provided by operating activities and the purchase of spare parts are presented as cash outflows in operating assets and liabilities-other assets.

Cash, Cash Equivalents

Accounts Receivable

Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method. Inventory costs include material, labor and overhead related to the manufacturing of medical devices.

Inventories consist of the following at December 31 (in thousands):



	2019		2018
Raw materials	$	119,709	$	104,104
Work in process	39,515		52,909
Finished goods	178,416		154,150
Total	$	337,640	$	311,163

Property, Plant and Equipment

Property, plant and equipment consist of the following at December 31 (in thousands):



	2019			2018
Machinery and equipment	$	219,057		$	203,431
Land, building and building improvements	230,454			212,283
Molds	60,155			59,700
Computer equipment and software	83,217			80,420
Furniture and fixtures	7,498			7,409
Instruments placed with customers¹	74,434			60,757
Construction in progress	101,425			70,864
Total property, plant and equipment, cost	776,240			694,864
Accumulated depreciation	(320,155		)	(262,223		)
Net property, plant and equipment	$	456,085		$	432,641

______________________________

¹Instruments placed with customers consist of drug-delivery and monitoring systems placed with customer under operating leases.

All property, plant and equipment are stated at cost. We use the straight-line method for depreciating property, plant and equipment over their estimated useful lives. Estimated useful lives are:



Buildings	15 - 30 years
Building improvements	15 - 30 years
Machinery, equipment and molds	2 - 15 years
Furniture, fixtures and office equipment	2 - 5 years
Computer equipment and software	3 - 5 years
Instruments placed with customers	3 - 10 years

Goodwill

The following table presents the changes in the carrying amount of our goodwill for 2019, 2018 and 2017 (in thousands):



	Total
Balance as of January 1, 2017	$	5,577
Goodwill acquired⁽¹⁾	6,536
Other	244
Balance as of December 31, 2017	12,357
Goodwill acquired⁽²⁾	1,300
Other⁽³⁾	(2,462		)
Balance as of December 31, 2018	11,195
Goodwill acquired⁽⁴⁾	20,026
Other	24
Balance as of December 31, 2019	$	31,245

______________________________

⁽¹⁾ In 2017, the goodwill acquired primarily relates to our acquisition of Medical Australia Limited ("MLA").

⁽²⁾ In 2018, we acquired the consulting arm of a small software company, which resulted in $1.3 million of goodwill.

⁽³⁾In 2018, "Other" relates to a $1.9 million measurement period adjustment on our MLA acquisition and foreign currency translation.

⁽⁴⁾In 2019, we acquired Pursuit Vascular, Inc. ("Pursuit"), which resulted in $19.1 million of goodwill. We also acquired a small foreign distributor, which resulted in $0.9 million of goodwill.

Intangible Assets

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):



	Weighted Average Amortization Life in Years	December 31, 2019
	Weighted Average Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	22,322	$	13,519	$	8,803
Customer contracts	12	10,122		5,506		4,616
Non-contractual customer relationships	9	57,296		19,787		37,509
Trademarks	4	425		425		—
Trade name	15	18,256		2,254		16,002
Developed technology	13	152,354		24,228		128,126
Non-compete	3	2,500		139		2,361
Total amortized intangible assets		$	263,275	$	65,858	$	197,417

Internally developed software*		$	13,991			$	13,991

Total intangible assets		$	277,266	$	65,858	$	211,408

____________________________

* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.



	Weighted Average	December 31, 2018
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	19,399	$	12,147	$	7,252
Customer contracts	9	5,319		5,272		47
Non-contractual customer relationships	9	57,916		13,363		44,553
Trademarks	4	425		425		—
Trade name	15	7,456		1,618		5,838
Developed technology	11	82,857		15,361		67,496
Total		$	173,372	$	48,186	$	125,186

Internally developed software*		$	8,235			$	8,235

Total intangible assets		$	181,607	$	48,186	$	133,421

____________________________

* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.

Amortization expense in 2019, 2018 and 2017 was $17.7 million, $16.6 million and $15.0 million, respectively.

As of December 31, 2019 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):



2020	$	21,692
2021	22,587
2022	22,303
2023	21,461
2024	21,371
Thereafter	88,003
Total	$	197,417

Our intangible assets that are not subject to amortization are reviewed annually for impairment or more often if there are indications of possible impairment. We perform our annual intangible assets impairment test in November of each year.

Long-Lived Assets

Investment Securities

Our investment securities consist of the following (in thousands):



	December 31, 2019
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	23,967		$	—	$	23,967
Long-term corporate bonds	—		—		—
Total investment securities	$	23,967	$	—	$	23,967

	December 31, 2018
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	37,329	$	—	$	37,329
Long-term corporate bonds	2,025		—		2,025
Total investment securities	$	39,354	$	—	$	39,354

Income Taxes

Foreign Currency

Revenue Recognition

Our software license renewals are considered to be transferred to a customer at a point in time at the start of each renewal period, therefore revenue is recognized at that time.

Arrangements with Multiple Deliverables

Shipping Costs

Costs to ship finished goods to our customers are included in cost of goods sold on the consolidated statements of operations.

Advertising Expenses

Post-retirement and Post-employment Benefits

Research and Development

Net Income Per Share

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands except per share data):



	Year ended December 31, (in thousands, except per share data)
	2019		2018		2017
Net income	$	101,035	$	28,793	$	68,644
Weighted average number of common shares outstanding (basic)	20,629		20,394		19,614
Dilutive securities	916		1,207		1,244
Weighted average common and common equivalent shares outstanding (diluted)	21,545		21,601		20,858
EPS - basic	$	4.90	$	1.41	$	3.50
EPS - diluted	$	4.69	$	1.33	$	3.29

New Accounting Pronouncements

Recently Adopted Accounting Standards

In February 2016, the FASB issued Accounting Standard Update ("ASU") No. 2016-02, Leases (Topic 842). The amendments in this update require an entity to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The updated guidance required a modified retrospective adoption. In July 2018, the FASB issued ASU No. 2018-11, Targeted Improvements. The amendments in this update provide entities with an additional (and optional) transition method to adopt the new lease requirements by allowing entities to initially apply the requirements by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The amendments in this update also provided lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease contract. This expedient is limited to circumstances in which the nonlease components otherwise would be accounted for under the new revenue guidance and both (1) the timing and pattern of transfer are the same for the nonlease components and associated lease component and (2) the lease component, if accounted for separately, would be classified as an operating lease. If the lessor uses this practical expedient they would account for the lease contract in accordance with Topic 606 if the nonlease component is the predominant component otherwise, the lessor should account for the combined component as an operating lease in accordance with Topic 842. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. This ASU clarifies certain language in ASU 2016-02 and corrects certain references and inconsistencies. We adopted these standards effective January 1, 2019 (see Note 5, Leases for a discussion of the impact and required disclosures).

In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The amendments in this update remove the second step of the impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The amendments in ASU 2017-04 are effective for the annual or interim impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this ASU effective April

1, 2019, which had no impact on our consolidated financial statements or related footnote disclosures. We adopted this ASU early ahead of our annual impairment test to reduce the complexity of the quantitative test if necessary.

Recently Issued Accounting Standards

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Topic 350): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal use software license. Costs to develop or obtain internal-use software that cannot be capitalized under subtopic 350-40, such as training costs and certain data conversion costs, also cannot be capitalized for a hosting arrangement that is a service contract. Therefore, an entity in a hosting arrangement that is a service contract determines which project stage (that is, preliminary project stage, application development stage, or post-implementation stage) an implementation activity relates to. Costs for implementation activities in the application development stage are capitalized depending on the nature of the costs, while costs incurred during the preliminary project and post-implementation stages are expensed as the activities are performed. The amendments in this update require the entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. The amendments in this update are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted this ASU effective January 1, 2020. This ASU will not have a material impact on our consolidated financial statements or related disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820. The amendments remove from disclosure: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels 3; and the valuation processes for Level 3 fair value measurements. The amendments also made the following disclosure modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The amendments also added the following disclosure requirements: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level 3 fair value measurements. The amendments in ASU 2018-02 are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. We adopted this ASU effective January 1, 2020. This ASU will not have a material impact on our consolidated financial statements or related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update amends the FASB's guidance on the impairment of financial instruments by requiring timelier recording of credit losses on loans and other financial instruments. The ASU adds an impairment model that is based on expected losses rather than incurred losses. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted as of the fiscal years beginning after December 15, 2018. The updated guidance requires a modified retrospective adoption. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. This update clarifies that receivables arising from operating leases are not within the scope of this guidance, instead, impairment of receivables arising from operating leases should be accounted for in accordance with the lease guidance. In November 2019, the FASB issued ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. We adopted these ASUs effective January 1, 2020. These ASUs will not have a material impact on our consolidated financial statements or related disclosures.

Accrued Liabilities an Other Long-term Liabilities (Tables)

12 Months Ended

Dec. 31, 2019

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities consist of the following (in thousands):



	December 31,
	2019		2018
Salaries and benefits	$	21,116	$	20,538
Incentive compensation	15,221		42,913
Accrued supply chain restructuring costs	23,119		—
Operating lease liability-ST	7,362		—
Accrued professional fees	4,782		15,996
Accrued product field action	2,096		5,316
Consigned inventory	—		1,118
Third-party inventory	—		1,089
Legal accrual	826		1,400
Accrued sales taxes	2,615		2,941
Warranties and returns	782		1,124
Deferred revenue	4,761		3,814
Accrued other taxes	4,054		3,213
Distribution fees	3,942		3,977
Accrued freight	11,238		10,953
Restructuring accrual	5,459		1,046
Contract liabilities-ST	1,935		—
Contract settlement	1,667		2,083
Accrued research and development	—		1,451
Other	6,801		9,848
	$	117,776	$	128,820

Other long-term liabilities consist of the following (in thousands):



	December 31,
	2019		2018
Operating lease liabilities-LT	$	28,896	$	—
Contract liabilities⁽¹⁾	472		14,020
Deferred revenue	94		468
Benefits	1,131		962
Accrued rent	1,642		1,779
Contract settlement	—		1,667
Other	585		1,696
	$	32,820	$	20,592

__________________________________________

⁽¹⁾ Consists of contracts with customers and suppliers that were valued at below market at the time of the HIS acquisition.

General and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consist of the following at December 31 (in thousands):



	2019		2018
Raw materials	$	119,709	$	104,104
Work in process	39,515		52,909
Finished goods	178,416		154,150
Total	$	337,640	$	311,163

Property, Plant and Equipment [Table Text Block]

Property, plant and equipment consist of the following at December 31 (in thousands):



	2019			2018
Machinery and equipment	$	219,057		$	203,431
Land, building and building improvements	230,454			212,283
Molds	60,155			59,700
Computer equipment and software	83,217			80,420
Furniture and fixtures	7,498			7,409
Instruments placed with customers¹	74,434			60,757
Construction in progress	101,425			70,864
Total property, plant and equipment, cost	776,240			694,864
Accumulated depreciation	(320,155		)	(262,223		)
Net property, plant and equipment	$	456,085		$	432,641

______________________________

¹Instruments placed with customers consist of drug-delivery and monitoring systems placed with customer under operating leases.

All property, plant and equipment are stated at cost. We use the straight-line method for depreciating property, plant and equipment over their estimated useful lives. Estimated useful lives are:



Buildings	15 - 30 years
Building improvements	15 - 30 years
Machinery, equipment and molds	2 - 15 years
Furniture, fixtures and office equipment	2 - 5 years
Computer equipment and software	3 - 5 years
Instruments placed with customers	3 - 10 years

Schedule of Intangible Assets and Goodwill [Table Text Block]

The following table presents the changes in the carrying amount of our goodwill for 2019, 2018 and 2017 (in thousands):



	Total
Balance as of January 1, 2017	$	5,577
Goodwill acquired⁽¹⁾	6,536
Other	244
Balance as of December 31, 2017	12,357
Goodwill acquired⁽²⁾	1,300
Other⁽³⁾	(2,462		)
Balance as of December 31, 2018	11,195
Goodwill acquired⁽⁴⁾	20,026
Other	24
Balance as of December 31, 2019	$	31,245

______________________________

⁽¹⁾ In 2017, the goodwill acquired primarily relates to our acquisition of Medical Australia Limited ("MLA").

⁽²⁾ In 2018, we acquired the consulting arm of a small software company, which resulted in $1.3 million of goodwill.

⁽³⁾In 2018, "Other" relates to a $1.9 million measurement period adjustment on our MLA acquisition and foreign currency translation.

Intangible Assets

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):



	Weighted Average Amortization Life in Years	December 31, 2019
	Weighted Average Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	22,322	$	13,519	$	8,803
Customer contracts	12	10,122		5,506		4,616
Non-contractual customer relationships	9	57,296		19,787		37,509
Trademarks	4	425		425		—
Trade name	15	18,256		2,254		16,002
Developed technology	13	152,354		24,228		128,126
Non-compete	3	2,500		139		2,361
Total amortized intangible assets		$	263,275	$	65,858	$	197,417

Internally developed software*		$	13,991			$	13,991

Total intangible assets		$	277,266	$	65,858	$	211,408

____________________________

* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.



	Weighted Average	December 31, 2018
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	19,399	$	12,147	$	7,252
Customer contracts	9	5,319		5,272		47
Non-contractual customer relationships	9	57,916		13,363		44,553
Trademarks	4	425		425		—
Trade name	15	7,456		1,618		5,838
Developed technology	11	82,857		15,361		67,496
Total		$	173,372	$	48,186	$	125,186

Internally developed software*		$	8,235			$	8,235

Total intangible assets		$	181,607	$	48,186	$	133,421

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

As of December 31, 2019 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):



2020	$	21,692
2021	22,587
2022	22,303
2023	21,461
2024	21,371
Thereafter	88,003
Total	$	197,417

Available-for-sale Securities [Table Text Block]

Our investment securities consist of the following (in thousands):



	December 31, 2019
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	23,967		$	—	$	23,967
Long-term corporate bonds	—		—		—
Total investment securities	$	23,967	$	—	$	23,967

	December 31, 2018
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	37,329	$	—	$	37,329
Long-term corporate bonds	2,025		—		2,025
Total investment securities	$	39,354	$	—	$	39,354

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands except per share data):



	Year ended December 31, (in thousands, except per share data)
	2019		2018		2017
Net income	$	101,035	$	28,793	$	68,644
Weighted average number of common shares outstanding (basic)	20,629		20,394		19,614
Dilutive securities	916		1,207		1,244
Weighted average common and common equivalent shares outstanding (diluted)	21,545		21,601		20,858
EPS - basic	$	4.90	$	1.41	$	3.50
EPS - diluted	$	4.69	$	1.33	$	3.29

Leases Lease Maturities (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

As of December 31, 2019, the maturities of our lease liabilities for each of the next five years are approximately (in thousands):



	Operating Leases
2020	$	8,850
2021	7,412
2022	6,621
2023	6,204
2024	5,896
Thereafter	7,765
Total Lease Payments	42,748
Less imputed interest	(6,490		)
Total	$	36,258

As of December 31, 2018, the maturities of our operating lease liabilities for each of the next five years were approximately (in thousands):



	Operating Leases
2019	$	8,326
2020	8,572
2021	6,489
2022	5,914
2023	5,615
Thereafter	13,235
Total Lease Payments⁽¹⁾	$	48,151

____________________________

⁽¹⁾The lease payment maturities as of December 31, 2018 are not calculated at present value.

Long-Term Obligations (Notes)

12 Months Ended

Dec. 31, 2019

Long-Term Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

LONG-TERM OBLIGATIONS

Five-year Revolving Credit Facility ("Credit Facility")

On November 8, 2017, we entered into a five-year Revolving Credit Facility ("Credit Facility") with various lenders for $150 million, with Wells Fargo Bank, N.A. as the administrative agent, swingline lender and issuing lender. As of December 31, 2019 and 2018, we had no borrowings and $150 million of availability under the Credit Facility. The Credit Facility matures on November 8, 2022.

The Credit Facility has an accordion feature that would enable us to increase the borrowing capacity of the Credit Facility by the greater of (i) $100 million and (ii) 2.00x Total Leverage.

In connection with the Credit Facility, for the year ended December 31, 2017, we incurred $1.4 million in financing costs, which were capitalized and are included in prepaid expenses and other current assets and other assets in our consolidated balance sheets, in accordance with the appropriate short-term or long-term classification. These fees are being amortized to interest expense over the remaining term of the Credit Facility.

Principal payments

Principal payments, when drawn on the Credit Facility, are made at our discretion with the entire unpaid amount due at maturity.

Interest rate

In general, borrowing under the Credit Facility (other than Swingline loans) bears interest, at our option, based on the Base Rate plus applicable margin or the London Interbank Offered Rate ("LIBOR") rate plus applicable margin, as defined below:

(A) Base Rate is defined as the highest of: (a) the Prime Rate; (b) the Federal Funds Rate plus 0.50%; and (c) the daily LIBOR (as defined below) for a one month Interest Period plus 1%.

(B) LIBOR Rate, as determined by the Administrative Agent, is defined as the rate per annum obtained by dividing (1) LIBOR by (2) 1.00 - Eurodollar Reserve Percentage.

Swingline loans will bear interest at the Base Rate plus the applicable Interest Margin. The Credit Facility has a per annum commitment fee (see table below) that will accrue on the unused amounts of the commitments under the Credit Facility.

The applicable interest margins and the commitment fee with respect to the Credit Facility shall be based on the Total Leverage Ratio pursuant to the following pricing grid:



Level	Consolidated Total Leverage Ratio	Commitment Fee	LIBOR +	Base Rate +
I	Less than 1.00 to 1.00	0.15%	1.25%	0.25%
II	Greater than or equal to 1.00 to 1.00 but less than 2.00 to 1.00	0.20%	1.50%	0.50%
III	Greater than or equal to 2.00 to 1.00 but less than 2.50 to 1.00	0.25%	1.75%	0.75%
IV	Greater than or equal to 2.50 to 1.00	0.30%	2.00%	1.00%

Guarantors and Collateral

Our obligations under the Credit Facility are unconditionally guaranteed, on a joint and several basis, by ICU Medical, Inc. and certain of our existing subsidiaries. Our obligations are secured by: (i) 100% of the equity interests of our guarantor subsidiaries; and (ii) all of the tangible and intangible personal property and assets related to us and our guarantor subsidiaries

(including, without limitation, all accounts, equipment, inventory and other goods, all instruments, intellectual property and other general intangibles, deposit accounts, securities accounts and other investment property and cash), and (iii) all products, profits and proceeds of the foregoing. Notwithstanding the foregoing, the collateral shall not include certain excluded property.

Debt Covenants

The Credit Facility contains certain financial covenants pertaining to Consolidated Fixed Charge Coverage and Consolidated Total Leverage Ratios. In addition, the Credit Facility has restrictions pertaining to limitations on debt, liens, negative pledges, loans, advances, acquisitions, other investments, dividends, distributions, redemptions, repurchases of equity interests, fundamental changes and asset sales and other dispositions, prepayments, redemptions and purchases of subordinated debt and other junior debt, transactions with affiliates, dividend and payment restrictions affecting subsidiaries, changes in line of business, fiscal year and accounting practices and amendment of organizational documents and junior debt documents.

The Consolidated Leverage Ratio is defined as the ratio of Consolidated Total Funded Indebtedness on such date, to Consolidated Adjusted EBITDA, as defined under the Credit Facility Agreement, for the most recently completed four fiscal quarters. The maximum Consolidated Leverage Ratio is not more than 3.00 to 1.00.

The Consolidated Fixed Charge Coverage Ratio is defined as the ratio of: (a) Consolidated Adjusted EBITDA less the sum of (i) capital expenditures, (ii) federal, state, local and foreign income taxes paid in cash and (iii) cash restricted payments made after the closing date, to (b) Consolidated Fixed Charges for the most recently completed four fiscal quarters, calculated on a pro forma basis. The minimum Consolidated Fixed Charge Coverage Ratio is 2.00 to 1.00.

We were in compliance with all financial covenants as of December 31, 2019.

Three-Year Interest-Only Senior Note

On February 3, 2017, we partially funded the acquisition of the HIS business from Pfizer with a $75 million Seller Note issued by Pfizer contemporaneous with the acquisition. We had fully repaid the seller note as of December 31, 2017.

Acquisitions Pursuit Vascular (Tables)

12 Months Ended

Dec. 31, 2019

Pursuit Vascular, Inc. [Member]

Business Acquisition [Line Items]

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

The following table summarizes the preliminary purchase price and the preliminary allocation of the purchase price related to the assets and liabilities purchased (in thousands):



Cash consideration for acquired assets, net	$	71,533
Fair value of contingent consideration	17,300
Total Estimated Consideration	$	88,833

Preliminary Purchase Price Allocation:
Trade receivables	$	973
Inventories	2,464
Prepaid expenses and other current assets	74
Property, plant and equipment	609
Intangible assets⁽¹⁾	82,300
Accounts payable	(215		)
Accrued liabilities	(2,065		)
Total identifiable net assets acquired	$	84,140
Goodwill - not tax deductible	19,116
Deferred tax liability	(14,423		)
Estimated Purchase Consideration	$	88,833

^{____________________________________________}

Accrued Liabilities an Other Long-term Liabilities

12 Months Ended

Dec. 31, 2019

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

ACCRUED LIABILITIES AND OTHER LONG-TERM LIABILITIES

Accrued liabilities consist of the following (in thousands):



	December 31,
	2019		2018
Salaries and benefits	$	21,116	$	20,538
Incentive compensation	15,221		42,913
Accrued supply chain restructuring costs	23,119		—
Operating lease liability-ST	7,362		—
Accrued professional fees	4,782		15,996
Accrued product field action	2,096		5,316
Consigned inventory	—		1,118
Third-party inventory	—		1,089
Legal accrual	826		1,400
Accrued sales taxes	2,615		2,941
Warranties and returns	782		1,124
Deferred revenue	4,761		3,814
Accrued other taxes	4,054		3,213
Distribution fees	3,942		3,977
Accrued freight	11,238		10,953
Restructuring accrual	5,459		1,046
Contract liabilities-ST	1,935		—
Contract settlement	1,667		2,083
Accrued research and development	—		1,451
Other	6,801		9,848
	$	117,776	$	128,820

Other long-term liabilities consist of the following (in thousands):



	December 31,
	2019		2018
Operating lease liabilities-LT	$	28,896	$	—
Contract liabilities⁽¹⁾	472		14,020
Deferred revenue	94		468
Benefits	1,131		962
Accrued rent	1,642		1,779
Contract settlement	—		1,667
Other	585		1,696
	$	32,820	$	20,592

__________________________________________

⁽¹⁾ Consists of contracts with customers and suppliers that were valued at below market at the time of the HIS acquisition.

Collaborative and Other Arrangements (Notes)	12 Months Ended
Collaborative and Other Arrangements (Notes)	Dec. 31, 2019
Collaborative and Other Arrangements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	COLLABORATIVE AND OTHER ARRANGEMENTS On February 3, 2017, we entered into two MSA's, (i) whereby Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) whereby we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSA's provide each party with mutually beneficial interests and both of the MSA's are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products. On February 3, 2017, as part of the HIS business acquisition, we had entered into an agreement with Pfizer, whereby Pfizer were to provide certain transitional services to us for finance, business technology, regulatory, human resources, global operations, procurement, quality and global commercial operation services ("Enabling Function Services"). We paid a monthly service fee for each service provided, and shared equally with Pfizer in certain set-up costs and, as applicable, service exit costs. Our share of the set-up costs and service exit costs, in the aggregate, were not to exceed $22.0 million. The service fees were subject to a fee cap of (i) $62.5 million during the initial twelve month period and (ii) $31.3 million during the subsequent six month period. Only the Enabling Function Services were subject to the fee cap, any services provided after expiration of the agreement or services that were not Enabling Function Services were to result in service fees outside the fee cap. The service fees were intended to reasonably approximate Pfizer’s cost of providing the Enabling Function Services. We had also entered into a reverse transitional services agreement, where we provided to Pfizer certain transitional services ranging in term from three to eighteen months. Services included support for real estate, research and development, infrastructure, logistics, quality, site operations, safety, commercial and finance, and regulatory support services. This transitional service agreement with Pfizer ended in 2018.

Statement of Comprehensive Income - USD ($)	12 Months Ended
Statement of Comprehensive Income - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net income	$ 101,035,000	$ 28,793,000	$ 68,644,000
Cash flow hedge adjustments, net of taxes of $392, $317 and $224 for the years ended December 31, 2019, 2018 and 2017, respectively	1,242,000	1,003,000	(365,000)
Foreign currency translation adjustment, net of taxes of $0, $0 and $56 for the years ended December 31, 2019, 2018 and 2017, respectively	372,000	(3,104,000)	6,694,000
Other adjustments, net of taxes of $0 for the years ended December 31, 2019, 2018 and 2017	(71,000)	115,000	(16,000)
Other Comprehensive Income (Loss), Net of Tax	1,543,000	(1,986,000)	6,313,000
Comprehensive income	102,578,000	26,807,000	74,957,000
Other Comprehensive Income (Loss), Cash Flow Hedge Adjustments, Tax	392,000	317,000	(224,000)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	0	0	56,000
Other Comprehensive (Income) Loss, Other Adjustments, Tax	$ 0	$ 0	$ 0

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

General and Summary of Significant Accounting Policies New Accounting Pronouncements (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	$ 40.4

Income Taxes Unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Unrecognized tax benefits [Abstract]
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions	$ 138	$ 0	$ 77
Unrecognized Tax Benefits, Increase Resulting from Acquisition	0	0	640
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	4,231	4,536	3,992
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	(3)	(146)	(12)
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations	(163)	(93)	(170)
Unrecognized Tax Benefits	$ 15,027	$ 10,824	$ 6,527	$ 2,000

Leases (Details) $ in Millions	12 Months Ended
Leases (Details) $ in Millions	Dec. 31, 2019 USD ($)
Leases [Abstract]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	$ 40.4
subsequenteventleasesminimumpayments	$ 21.8

Revenue (Details) $ in Millions	12 Months Ended
Revenue (Details) $ in Millions	Dec. 31, 2018 USD ($)
Revenue from Contract with Customer [Abstract]
Cumulative Effect on Retained Earnings, Net of Tax	$ 6.3

Geographic Information and Significant Customers Geographic Information and Significant Customers (Notes)

12 Months Ended

Dec. 31, 2019

Geographic Areas, Long-Lived Assets [Abstract]

Information by Geographic Area and Customer Concentration [Text Block]

GEOGRAPHIC INFORMATION AND SIGNIFICANT CUSTOMERS

Significant Customers

We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. We do not currently derive a significant portion of our revenues from any one customer.

Geographic Information

The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):



	As of December 31,
	2019		2018
Costa Rica	$	96,442	$	81,920
Mexico	69,141		64,242
Other LATAM	31,905		22,828
Canada	4,769		4,545
Italy	7,921		7,819
Spain	6,411		6,516
Other Europe	3,135		2,427
APAC	17,200		15,152
Total Foreign	$	236,924	$	205,449
United States	539,316		489,415
Worldwide Total	$	776,240	$	694,864

Acquisitions Pursuit Vascular Table (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2017
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability, Noncurrent	$ 17,300	$ 19,000
Pursuit Vascular, Inc. [Member]
Business Acquisition [Line Items]
Payment to acquire business, net of working capital adjustments	71,533
Business Combination, Contingent Consideration, Liability, Noncurrent	17,300
Business Combination, Consideration Transferred	88,833
Business Combination, Acquired Receivable, Fair Value	973
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	2,464
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets	74
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	609
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	82,300
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	(215)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other	(2,065)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	84,140
Business Acquisition, Goodwill, Expected Tax Deductible Amount	19,116
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent	$ (14,423)

Restructuring, Strategic Transaction and Integration Schedule of Restructuring and Related Costs (Tables)

12 Months Ended

Dec. 31, 2019

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs [Table Text Block]

The following table summarizes the activity for the restructuring-related charges discussed above and related accrual (in thousands):



	Accrued Balance January 1, 2018		Charges incurred		Payments			Other Adjustments			Accrued Balance December 31, 2018		Charges incurred		Payments			Other Adjustments		Accrued Balance December 31, 2019
Severance pay and benefits	$	915	$	4,311	$	(4,549	)	$	—		$	677	$	5,634	$	(2,433	)	$	—	$	3,878
Employment agreement buyout	1,114		—		(368		)	(7		)	739		—		(279		)	—		460
Retention and facility closure expenses	—		160		(160		)	—			—		2,741		(1,530		)	—		1,211
	$	2,029	$	4,471	$	(5,077	)	$	(7	)	$	1,416	$	8,375	$	(4,242	)	$	—	$	5,549

Restructuring, Strategic Transaction and Integration (Notes)

12 Months Ended

Dec. 31, 2019

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

RESTRUCTURING, STRATEGIC TRANSACTION AND INTEGRATION

Restructuring and strategic transaction and integration expenses were $80.6 million, $105.4 million and $78.0 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Restructuring

Restructuring charges were $8.4 million, $4.5 million and $18.8 million for the years ended December 31, 2019, 2018 and 2017, respectively, and are included in the above restructuring, strategic transaction and integration amounts on a separate line item in our consolidated statement of operations.

During the year ended December 31, 2019, restructuring charges were primarily related to severance and facility closure costs. These charges were primarily related to a one-time charge to move our U.S. pump service depot to our existing Salt Lake City facility and other plant restructuring. The cumulative amount incurred to date in connection with the HIS acquisition is $25.1 million.

In 2018 and 2017, we incurred restructuring charges related to the acquisition of the HIS business (see Note 2, Acquisitions). The restructuring charges were incurred as a result of integrating the acquired operations into our business and include severance costs related to involuntary employee terminations and facility exit costs related to the closure of the Dominican Republic manufacturing facilities acquired from Pfizer.

In 2015, we incurred restructuring charges related to an agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement, the buy-out, including payroll taxes, will be paid in equal monthly installments until December 2020. The remaining payments owed are included in accrued liabilities in our consolidated balance sheet.

The following table summarizes the activity for the restructuring-related charges discussed above and related accrual (in thousands):



	Accrued Balance January 1, 2018		Charges incurred		Payments			Other Adjustments			Accrued Balance December 31, 2018		Charges incurred		Payments			Other Adjustments		Accrued Balance December 31, 2019
Severance pay and benefits	$	915	$	4,311	$	(4,549	)	$	—		$	677	$	5,634	$	(2,433	)	$	—	$	3,878
Employment agreement buyout	1,114		—		(368		)	(7		)	739		—		(279		)	—		460
Retention and facility closure expenses	—		160		(160		)	—			—		2,741		(1,530		)	—		1,211
	$	2,029	$	4,471	$	(5,077	)	$	(7	)	$	1,416	$	8,375	$	(4,242	)	$	—	$	5,549

Strategic Transaction and Integration Expenses

During the years ended December 31, 2019, 2018 and 2017, we incurred $72.2 million, $100.9 million and $59.2 million, respectively, in transaction and integration costs. These costs were primarily related to the acquisition and integration of HIS business, (see Note 2, Acquisitions). The integration expenses for the year ended December 31, 2019, included a one-time strategic supply chain restructuring charge of $22.1 million, which reduces our contracted commitments to our third party manufacturer and charges related to our Pfizer separation costs, which included a $12.7 million non-cash write-off of related assets.

Income Taxes Tax benefit from exercise of stock options (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Share-based Payment Arrangement, Exercise of Option, Tax Benefit	$ 9,653	$ 12,617	$ 20,004
Share-based Payment Arrangement, Expense, Tax Benefit	$ 4,840	$ 5,706	$ 7,247

Leases (Notes)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Leases of Lessee Disclosure [Text Block]

LEASES

Adoption of ASC Topic 842, "Lease Accounting"

We adopted ASU No. 2016-02, Leases (ASC Topic 842), effective January 1, 2019 on a modified retrospective transition method through a cumulative-effect adjustment at the beginning of the first quarter of 2019. We elected the 'package of practical expedients', which permitted us not to reassess our prior conclusions about lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us. We elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, we did not recognize right-of-use ("ROU") assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. Furthermore, we elected the practical expedient to not separate lease and non-lease components for all of our leases, non-lease components are primarily common area maintenance charges that we combine with the lease component when applying this ASU.

The impact of adopting this standard was the recognition of ROU assets and lease liabilities for our operating leases of $40.4 million as of January 1, 2019. The adoption of ASC 842 did not have a material impact on our consolidated earnings or on our cash flows.

Leases

We determine if an arrangement is a lease at inception. Our operating leases with a term greater than one year are included in operating lease ROU assets, accrued liabilities, and other long-term liabilities on our consolidated balance sheets.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Most of our leases do not provide an implicit rate, therefore we use our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term based on the information available at commencement date. The operating lease ROU asset excludes initial direct costs incurred. Our lease terms include options to extend when it is reasonably certain that we will exercise that option. All of our operating leases have stated lease payments, which may include fixed rental increases. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

We have operating leases for corporate, R&D and sales and support offices, device service centers, distribution warehouses and certain equipment. Our leases have original lease terms of one year to fifteen years, some of which include options to extend the leases for up to an additional five years. For all of our leases, we do not include optional periods of extension in our current lease terms for the exercise of options to extend is not reasonably certain.

The following table presents the components of our lease cost (in thousands):



	For the year ended December 31, 2019
Operating lease cost	$	10,011

Short-term lease cost	322

Total lease cost	$	10,333

The following table presents the supplemental cash flow information related to our leases (in thousands):



	For the year ended December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	10,344

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	3,230

The following table presents the supplemental balance sheet information related to our leases (in thousands, except lease term and discount rate):



	As of December 31, 2019
Operating leases
Operating lease right-of-use assets	$	34,465

Accrued liabilities	$	7,362
Other long-term liabilities	28,896
Total operating lease liabilities	$	36,258

Weighted Average Remaining Lease Term
Operating leases	6 years

Weighted Average Discount Rate
Operating leases	5.57		%

As of December 31, 2019, the maturities of our lease liabilities for each of the next five years are approximately (in thousands):



	Operating Leases
2020	$	8,850
2021	7,412
2022	6,621
2023	6,204
2024	5,896
Thereafter	7,765
Total Lease Payments	42,748
Less imputed interest	(6,490		)
Total	$	36,258

As of December 31, 2018, the maturities of our operating lease liabilities for each of the next five years were approximately (in thousands):



	Operating Leases
2019	$	8,326
2020	8,572
2021	6,489
2022	5,914
2023	5,615
Thereafter	13,235
Total Lease Payments⁽¹⁾	$	48,151

____________________________

⁽¹⁾The lease payment maturities as of December 31, 2018 are not calculated at present value.

During the third quarter 2019, we signed a ten-year lease for a 610,806 square foot warehouse. The commencement of the lease is not expected until the first quarter of 2020 subject to the completion of landlord build-outs which will make the space available for use. Over the ten-year lease term, we expect the lease payments to total at least $21.8 million.

Acquisitions Pursuit Vascular Text (Details) - Pursuit Vascular, Inc. [Member] $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Payments to Acquire Businesses, Gross	$ 75.0
contingent consideration gross	$ 50.0

Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details) - Cash Flow Hedging [Member] - Cost of Sales [Member] - Foreign Exchange Forward [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ 2,550	$ 2,063	$ 296
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion	$ 916	$ 743	$ 885

General and Summary of Significant Accounting Policies Property and Equipment #1 (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	$ 776,240	$ 694,864
Accumulated Depreciation	320,155	262,223
Net property and equipment	456,085	432,641
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	219,057	203,431
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	230,454	212,283
Molds [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	60,155	59,700
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	83,217	80,420
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	7,498	7,409
Instruments Placed with Customers [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	74,434	60,757
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	$ 101,425	$ 70,864

Revenue (Tables)

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:



	For the year ended December 31,
	2019				2018				2017
Product line	Revenue		% of Revenue		Revenue		% of Revenue		Revenue		% of Revenue
Infusion Consumables	$	477,611	37	%	$	483,039	35	%	$	365,665	28	%
Infusion Systems	328,282		26	%	355,484		25	%	290,207		23	%
IV Solutions	414,971		33	%	507,985		36	%	521,963		40	%
Critical Care	45,344		4	%	53,532		4	%	49,961		4	%
Other	—		—	%	—		—	%	64,817		5	%
Total Revenues	$	1,266,208	100	%	$	1,400,040	100	%	$	1,292,613	100	%

We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.

The following table represents our revenues disaggregated by geography (in thousands):



	For the year ended December 31,
Geography	2019		2018		2017
Europe, the Middle East and Africa	$	130,530	$	134,363	$	119,934
Other Foreign	212,336		210,996		192,640
Total Foreign	342,866		345,359		312,574
United States	923,342		1,054,681		980,039
Total Revenues	$	1,266,208	$	1,400,040	$	1,292,613

Domestic sales accounted for 73%, 75% and 76% of total revenue in 2019, 2018 and 2017, respectively. International sales accounted for 27%, 25% and 24% of total revenue in 2019, 2018 and 2017, respectively.

Contract with Customer, Asset and Liability [Table Text Block]

Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10, Accrued Liabilities and Other Long-term liabilities). The following table presents our changes in the contract balances for the years ended December 31, 2019 and 2018, (in thousands):



	Contract Liabilities
Beginning balance, January 1, 2018	$	(7,066	)
Equipment revenue recognized	6,696
Equipment revenue deferred due to implementation	(4,196		)
Software revenue recognized	6,553
Software revenue deferred due to implementation	(6,269		)
Ending balance, December 31, 2018	$	(4,282	)
Equipment revenue recognized	8,807
Equipment revenue deferred due to implementation	(8,794		)
Software revenue recognized	3,953
Software revenue deferred due to implementation	(4,539		)
Ending balance, December 31, 2019	$	(4,855	)

Income Taxes Income from continuing operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Foreign Earnings Repatriated	$ 78,500
Income (Loss) from Continuing Operations before Income Taxes, Domestic	32,849	$ (8,600)	$ 59,872
Income (Loss) from Continuing Operations before Income Taxes, Foreign	$ 81,858	$ 30,974	$ (8,589)

General and Summary of Significant Accounting Policies Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
NET INCOME PER SHARE
Net Income	$ 20,641	$ 26,563	$ 22,833	$ 30,998	$ (7,355)	$ 219	$ 31,054	$ 4,875	$ 101,035	$ 28,793	$ 68,644
Weighted average number of common shares outstanding (basic)									20,629,000	20,394,000	19,614,000
Weighted Average Number Diluted Shares Outstanding Adjustment									916,000	1,207,000	1,244,000
Weighted Average common and common equivalent shares outstandding (diluted)									21,545,000	21,601,000	20,858,000
Basic	$ 1.00	$ 1.29	$ 1.11	$ 1.51	$ (0.36)	$ 0.01	$ 1.53	$ 0.24	$ 4.90	$ 1.41	$ 3.50
Diluted	$ 0.96	$ 1.24	$ 1.06	$ 1.44	$ (0.36)	$ 0.01	$ 1.44	$ 0.23	$ 4.69	$ 1.33	$ 3.29
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									10,760	5,300	337

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Acquisitions Hospira (Tables)

12 Months Ended

Dec. 31, 2019

Hospira [Member]

Business Acquisition [Line Items]

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets and liabilities purchased (in thousands, except per share data):



Cash consideration for acquired assets	$	180,785
Fair value of Seller Note	75,000
Fair value of contingent consideration payable to Pfizer (long-term)	19,000

Issuance of ICU Medical, Inc. common shares:
Number of shares issued to Pfizer	3,200
Price per share (ICU's trading closing share price on the Closing Date)	$	140.75
Market price of ICU shares issued to Pfizer	$	450,400
Less: Discount due to lack of marketability of 8.3%	(37,261		)
Equity portion of purchase price	413,139
Total Consideration	$	687,924

Purchase Price Allocation:
Cash and cash equivalents	$	31,082
Trade receivables	362
Inventories	417,622
Prepaid expenses and other assets	13,911
Property, plant and equipment	288,134
Intangible assets⁽¹⁾	131,000
Other assets	29,270
Accounts payable	(12,381		)
Accrued liabilities	(47,936		)
Long-term liabilities⁽²⁾	(67,170		)
Total identifiable net assets acquired	$	783,894
Deferred tax, net	(25,080		)
Estimated Gain on Bargain Purchase	(70,890		)
Estimated Purchase Consideration	$	687,924

______________________________

⁽²⁾Long-term liabilities primarily consisted of contract liabilities, product liabilities and long-term employee benefits.

Fair Value Measurement Fair Value Measurements, Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investment securities	$ 23,967	$ 37,329
LONG-TERM INVESTMENT SECURITIES	0	2,025
Assets, Fair Value Disclosure	26,333	39,354
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investment securities	0	0
LONG-TERM INVESTMENT SECURITIES		0
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investment securities	23,967	37,329
LONG-TERM INVESTMENT SECURITIES		2,025
Assets, Fair Value Disclosure	26,333	39,354
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investment securities	0	0
LONG-TERM INVESTMENT SECURITIES		0
Assets, Fair Value Disclosure	0	0
Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	2,366	187
Prepaid Expenses and Other Current Assets [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Prepaid Expenses and Other Current Assets [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	2,366	187
Prepaid Expenses and Other Current Assets [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		545
Other Assets [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		0
Other Assets [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		545
Other Assets [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		0
Earn-out liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	17,300	47,400
Earn-out liability [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	0	0
Earn-out liability [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	0	0
Earn-out liability [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	17,300	47,400
Liabilities, Total [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	17,300	47,400
Liabilities, Total [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	0	0
Liabilities, Total [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	0	0
Liabilities, Total [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	$ 17,300	$ 47,400

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income	$ 101,035	$ 28,793	$ 68,644
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	76,916	74,735	66,569
Operatingleaserightofuseassetamortization	8,294	0	0
Provision for doubtful accounts	14,882	781	2,308
Provision for warranty and returns	(134)	5,353	845
Stock compensation	21,918	24,241	19,352
Loss (gain) on disposal of property and equipment	12,872	8,867	3,778
Productrationalization	0	12,696	0
Impairment of Intangible Assets, Finite-lived	0	5,000	0
Bond premium amortization	135	342	103
Debt issuance cost amortization	288	288	48
Impairment of assets held for sale	0	269
Impairment of assets held for sale			0
Bargain Purchase Gain	0	0	(70,890)
Change in fair value of contingent earn-out	(47,400)	20,400	8,000
Sparepartsusage	24,301	7,310	4,820
Other	447	3,856	(220)
Changes in operating assets and liabilities
Accounts receivable	(23,684)	(76,742)	(54,533)
Inventories	(24,997)	(21,770)	181,699
Prepaid expenses and other assets	8,588	3,719	(29,652)
Increase (Decrease) in Due from Related Parties, Current	0	97,443	(95,309)
Increase (Decrease) in Other Operating Assets	(29,837)	(9,086)	(6,975)
Accounts payable	(2,697)	23,270	46,648
Accrued liabilities	(43,689)	(29,553)	33,813
Income taxes, including excess tax benefits and deferred income taxes	4,680	(19,997)	(24,625)
Net cash provided by operating activities	101,918	160,215	154,423
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(97,312)	(92,720)	(74,479)
Proceeds from sale of assets	33	765	2
Proceeds from the disposal of assets held for sale	0	13,000	0
Intangible asset additions	(8,728)	(8,059)	(5,203)
Business acquisitions, net of cash acquired	(76,133)	(1,300)	(162,448)
Purchases of investment securities	(26,040)	(30,496)	(24,743)
Proceeds from sale of investment securities	41,292	15,440	0
Net cash (used in) provided by investing activities	(166,888)	(103,370)	(266,871)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of Long-term obligations	0	0	(75,000)
Proceeds from exercise of stock options	7,732	14,275	32,003
Proceeds from employee stock purchase plan	0	0	2,705
Purchase of treasury stock	(18,639)	(6,252)	(4,057)
Net cash (used in) provided by financing activities	(10,907)	8,023	(44,349)
Effect of exchange rate changes on cash	(234)	(10,159)	1,787
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(76,111)	54,709	(155,010)
CASH AND CASH EQUIVALENTS, beginning of period	344,781	290,072	445,082
CASH AND CASH EQUIVALENTS, end of period	268,670	344,781	290,072
SUPPLEMENTAL DISCLSOURE OF CASH FLOW INFORMATION
Cash paid during the year for income taxes	9,675	12,598	5,109
Interest Paid, Excluding Capitalized Interest, Operating Activities	549	709	2,047
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES
Accounts payable for property and equipment	13,912	26,522	5,376
Fair value of assets acquired	91,019		886,569
Cash paid for acquisitions, net of cash acquired	(76,133)		(162,448)
Proceeds from Issuance of Debt			(75,000)
Estimated working capital adjustment	0		4,253
Contingent consideration	(17,300)		(19,000)
Issuance of common stock for acquisitions	0		(413,139)
Bargain Purchase Gain	0	0	(70,890)
Goodwill, Acquired During Period	20,026	$ 1,300	6,536
Liabilities Assumed	$ (17,612)		(156,881)
Hospira [Member]
Adjustments to reconcile net income to net cash provided by operating activities:
Bargain Purchase Gain			(70,890)
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES
Proceeds from Issuance of Debt			(75,000)
Contingent consideration			(19,000)
Issuance of common stock for acquisitions			(413,139)
Bargain Purchase Gain			$ (70,890)

Income Taxes Income tax disclosure (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

Income from continuing operations before taxes consisted of the following (in thousands):



	Year Ended December 31,
	2019		2018			2017
United States	$	32,849	$	(8,600	)	$	59,872
Foreign	81,858		30,974			(8,589		)
	$	114,707	$	22,374		$	51,283

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The (benefit) provision for income taxes consisted of the following (in thousands):



	Year Ended December 31,
	2019			2018			2017
Current:
Federal	$	6,851		$	492		$	2,774
State	2,532			1,865			2,263
Foreign	7,994			9,136			3,170
	17,377			11,493			8,207
Deferred:
Federal	$	(6,720	)	$	(9,118	)	$	(20,878	)
State	(325		)	(3,072		)	(4,619		)
Foreign	3,340			(5,722		)	(71		)
	(3,705		)	(17,912		)	(25,568		)
	$	13,672		$	(6,419	)	$	(17,361	)

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

A reconciliation of the provision for income taxes at the statutory rate to our effective tax rate is as follows (dollars in thousands):



	Year Ended December 31,
	2019					2018					2017
	Amount			Percent		Amount			Percent		Amount			Percent
Federal tax at the expected statutory rate	$	24,088		21.0	%	$	4,699		21.0	%	$	17,950		35.0	%
State income tax, net of federal effect	1,269			1.1	%	927			4.1	%	(403		)	(0.8	)%
Tax credits	(2,896		)	(2.5	)%	(4,961		)	(22.2	)%	(2,783		)	(5.4	)%
Global intangible low-taxed income	6,118			5.3	%	2,363			10.6	%	—			—	%
Foreign income tax differential	(5,939		)	(5.2	)%	(2,944		)	(13.2	)%	3,481			6.8	%
Stock based compensation	(8,446		)	(7.4	)%	(11,040		)	(49.3	)%	(18,958		)	(37.0	)%
Impact of the Tax Act	—			—	%	826			3.7	%	3,076			6.0	%
IP installment sale and repatriation	(2,118		)	(1.8	)%	3,252			14.5	%	3,367			6.6	%
Bargain purchase gain	—			—	%	—			—	%	(24,811		)	(48.4	)%
Section 162(m)	203			0.2	%	456			2.0	%	595			1.2	%
Other	1,393			1.2	%	3			0.1	%	1,125			2.2	%
	$	13,672		11.9	%	$	(6,419	)	(28.7	)%	$	(17,361	)	(33.8	)%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The components of our deferred income tax assets (liabilities) are as follows (in thousands):



	December 31,
	2019			2018
Deferred tax asset:
Accruals/other	2,632			11,109
Contingent consideration	—			12,451
Net operating loss carryforwards	—			12,686
Acquired future tax deductions	8,711			10,722
Stock-based compensation	9,654			10,775
Foreign currency translation adjustments	2,716			3,108
Tax credits	11,331			14,470
Inventory reserves	4,305			5,674
Allowance for doubtful accounts	4,242			830
Accrued restructuring	7,072			182
Chargebacks, discounts, customer concessions	20,975			—
Valuation allowance	(3,677		)	(5,436		)
	$	67,961		$	76,571
Deferred tax liability:
State income taxes	$	2,600		$	2,639
Foreign	997			612
Depreciation and amortization	23,839			35,387
Section 481(a) adjustment - change in accounting method	14,618			—
	$	42,054		$	38,638

Deferred tax asset, net	$	25,907		$	37,933

Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]

The following table summarizes our cumulative gross unrecognized tax benefits (in thousands):



	Year Ended December 31,
	2019			2018			2017
Beginning balance	$	10,824		$	6,527		$	2,000
Increases to prior year tax positions	138			—			77
Increases due to acquisitions	—			—			640
Increases to current year tax positions	4,231			4,536			3,992
Decreases to prior year tax positions	(3		)	(146		)	(12		)
Decrease related to lapse of statute of limitations	(163		)	(93		)	(170		)
Ending balance	$	15,027		$	10,824		$	6,527

Income Taxes Change in taxes payable (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Income Tax Disclosure [Abstract]
Increase (Decrease) in Income Taxes Payable	$ 4.2

Leases Balance Sheet Lease Accounts (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Assets and Liabilities, Leases [Table Text Block]

The following table presents the supplemental balance sheet information related to our leases (in thousands, except lease term and discount rate):



	As of December 31, 2019
Operating leases
Operating lease right-of-use assets	$	34,465

Accrued liabilities	$	7,362
Other long-term liabilities	28,896
Total operating lease liabilities	$	36,258

Weighted Average Remaining Lease Term
Operating leases	6 years

Weighted Average Discount Rate
Operating leases	5.57		%

Long-Term Obligations Senior Note (Details) $ in Millions	Dec. 31, 2019 USD ($)
Debt Disclosure [Abstract]
Senior Notes	$ 75

Share Based Award Options exercised data (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Intrinsic value of options exercised	$ 22,976	$ 51,105	$ 71,283
Cash received from exercise of stock options	7,732	14,275	32,003
Tax benefit from stock option exercises	$ 9,653	$ 12,617	$ 20,004

Commitments and Contingencies Contingencies (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
contract settlement	$ 12.7		$ 28.9
Hospira [Member]
Business Acquisition [Line Items]
contingent consideration gross		$ 225.0		$ 225.0
Pursuit Vascular, Inc. [Member]
Business Acquisition [Line Items]
contingent consideration gross		$ 50.0

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2019

Stockholders' Equity Attributable to Parent [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The components of AOCI, net of tax, were as follows (in thousands):



	Foreign Currency Translation Adjustments			Unrealized Gains on Cash Flow Hedges			Other Adjustments			Total
Balance as of January 1, 2017	$	(21,272	)	$	—		$	—		$	(21,272	)
Other comprehensive income (loss) before reclassifications	6,694			184			(16		)	6,862
Amounts reclassified from AOCI	—			(549		)	—			(549		)
Other comprehensive income (loss)	6,694			(365		)	(16		)	6,313
Balance as of December 31, 2017	(14,578		)	(365		)	(16		)	(14,959		)
Other comprehensive (loss) income before reclassifications	(3,104		)	1,568			115			(1,421		)
Amounts reclassified from AOCI	—			(565		)	—			(565		)
Other comprehensive (loss) income	(3,104		)	1,003			115			(1,986		)
Balance as of December 31, 2018	$	(17,682	)	$	638		$	99		$	(16,945	)
Other comprehensive income (loss) before reclassifications	372			1,938			(71		)	2,239
Amounts reclassified from AOCI	—			(696		)	—			(696		)
Other comprehensive income (loss)	372			1,242			(71		)	1,543
Balance as of December 31, 2019	$	(17,310	)	$	1,880		$	28		$	(15,402	)

Leases Lease Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 8,850	$ 8,326
Lessee, Operating Lease, Liability, Payments, Due Year Two	7,412	8,572
Lessee, Operating Lease, Liability, Payments, Due Year Three	6,621	6,489
Lessee, Operating Lease, Liability, Payments, Due Year Four	6,204	5,914
Lessee, Operating Lease, Liability, Payments, Due Year Five	5,896	5,615
Lessee, Operating Lease, Liability, Payments, Due after Year Five	7,765	13,235
Lessee, Operating Lease, Liability, Payments, Due	42,748	$ 48,151
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(6,490)
Operating Lease, Liability	$ 36,258

Fair Value Measurement Fair Value Inputs, Liabilities, Pursuit Quantitative Information (Details) - Pursuit Vascular, Inc. [Member]	Dec. 31, 2019	Nov. 02, 2019
Revenue/Gross Profit Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.2000	0.2000
Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.1500	0.1500
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0155	0.0155
Credit Risk [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0600	0.0600

Acquisitions Hospira Intangible (Details) - Hospira [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 131,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	9 years
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 48,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	8 years
Pumps and dedicated sets [Domain]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 44,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
developed technology-consumables [Domain]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 34,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
In Process Research and Development [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	$ 5,000

Fair Value Measurement Text (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2017
Hospira [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
contingent consideration gross	$ 225	$ 225

Fair Value Measurement (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]



	Earn-out Liability
Contingent earn-out liability, January 1, 2017	$	—
Acquisition date fair value estimate of earn-out	19,000
Change in fair value of contingent earn-out (included in income from operations as a separate line item)	8,000
Contingent earn-out liability, December 31, 2017	$	27,000
Acquisition date fair value estimate of earn-out	—
Change in fair value of contingent earn-out (included in income from operations as a separate line item)	20,400
Contingent earn-out liability, December 31, 2018	47,400
Acquisition date fair value estimate of earn-out⁽¹⁾	17,300
Change in fair value of contingent earn-out (included in income from operations as a separate line item)	(47,400		)
Contingent earn-out liability, December 31, 2019	$	17,300

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at December 31, 2019
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale debt securities:
Short-term	$	23,967	$	—	$	23,967	$	—
Foreign exchange forwards:
Prepaid expenses and other current assets	2,366		—		2,366		—
Total Assets	$	26,333	$	—	$	26,333	$	—

Liabilities:

Earn-out liability	$	17,300	$	—	$	—	$	17,300
Total Liabilities	$	17,300	$	—	$	—	$	17,300



	Fair value measurements at December 31, 2018
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale debt securities:
Short-term	$	37,329	$	—	$	37,329	$	—
Long-term	2,025		—		2,025		—
Foreign exchange forwards:
Prepaid expenses and other current assets	187		$	—	$	187	$	—
Other assets	545		$	—	$	545	$	—
Total Assets	$	39,354	$	—	$	39,354	$	—

Liabilities:

Earn-out liability	$	47,400	$	—	$	—	$	47,400
Total Liabilities	$	47,400	$	—	$	—	$	47,400

Hospira [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

HIS Earn-out



Simulation Input	As of December 31, 2018		As of December 31, 2017		At Acquisition February 3, 2017
Adjusted EBITDA Volatility	30.00	%	26.00	%	29.00	%
WACC	8.25	%	8.75	%	10.00	%
20-year risk free rate	2.87	%	2.58	%	2.82	%
Market price of risk	5.24	%	5.99	%	6.93	%
Cost of debt	5.25	%	4.08	%	4.16	%

Pursuit Vascular, Inc. [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

Pursuit Earn-out



Simulation Input	As of December 31, 2019		At Acquisition November 2, 2019
Revenue/Gross Profit Volatility	20.00	%	20.00	%
Discount Rate	15.00	%	15.00	%
Risk free rate	1.55	%	1.55	%
Counter Party Risk	6.00	%	6.00	%

General and Summary of Significant Accounting Policies Intangible Assets #2 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Amortization of Intangible Assets	$ 17.7	$ 16.6	$ 15.0

Acquisitions Pursuit Vascular Intangible (Details) - Pursuit Vascular, Inc. [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 82,300
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 69,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 10,800
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 2,500
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	3 years

Income Taxes Effective tax rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Percent [Abstract]
GILTItaxexpense	$ 6,118	$ 2,363	$ 0
GILTItaxexpensepercent	5.30%	10.60%	0.00%
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	$ 114,707	$ 22,374	$ 51,283
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	24,088	4,699	17,950
Income Tax Reconciliation, State and Local Income Taxes	1,269	927	(403)
Income Tax Reconciliation, Tax Credits	(2,896)	(4,961)	(2,783)
Income Tax Reconciliation, Foreign Income Tax Rate Differential	$ (5,939)	$ (2,944)	$ 3,481
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	35.00%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes	1.10%	4.10%	(0.80%)
Effective Income Tax Rate Reconciliation, Tax Credits	(2.50%)	(22.20%)	(5.40%)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential	(5.20%)	(13.20%)	6.80%
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount	$ (8,446)	$ (11,040)	$ (18,958)
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent	(7.40%)	(49.30%)	(37.00%)
Effective Income Tax Rate, Continuing Operations	11.90%	(28.70%)	(33.80%)
Tax reform	$ 0	$ 826	$ 3,076
EffectiveIncomeTaxRateREconciliationTaxReform	0	0.037	0.060
EffectiveIncomeTaxRateReconciliationIPMigration	$ (2,118)	$ 3,252	$ 3,367
EffectiveTaxRateReconciliationIPMigrationPercent	(0.018)	0.145	0.066
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	$ 1,393	$ 3	$ 1,125
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent	1.20%	0.10%	2.20%
EffectiveIncomeTaxRateReconciliationBargainPurchaseGain	$ 0	$ 0	$ (24,811)
EffectiveTaxRateReconciliationBargainPurchaseGainPercent	0	0	(0.484)
Effectiveincometaxreconciliation,nondeductiblecompensation	$ 203	$ 456	$ 595
Effectivetaxratereconciliationnondeductiblecomppercent	0.20%	2.00%	1.20%
Income Tax Expense (Benefit)	$ 13,672	$ (6,419)	$ (17,361)

Revenue (Notes)

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

Our primary product lines are Infusion Consumables, Infusion Systems, IV Solutions and Critical Care. The vast majority of our sales of these products are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment.

Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to our distribution customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end-customers at prices determined under a contract between us and the end-customer. We use information available at the time and our historical experience to estimate and record provisions for chargebacks.

We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative selling price, and recognize revenue over the period the warranty service is provided. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.

Arrangements with Multiple Performance Obligations

We also enter into arrangements which include multiple performance obligations, see Note 1, Basis of Presentation and Summary of Significant Accounting Policies.

The most significant judgments related to these arrangements include:


•	Identifying the various performance obligations of these arrangements.


•	Estimating the relative standalone selling price of each performance obligation, typically using directly observable method or calculated on a cost plus margin basis method.

Revenue disaggregated

The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:



	For the year ended December 31,
	2019				2018				2017
Product line	Revenue		% of Revenue		Revenue		% of Revenue		Revenue		% of Revenue
Infusion Consumables	$	477,611	37	%	$	483,039	35	%	$	365,665	28	%
Infusion Systems	328,282		26	%	355,484		25	%	290,207		23	%
IV Solutions	414,971		33	%	507,985		36	%	521,963		40	%
Critical Care	45,344		4	%	53,532		4	%	49,961		4	%
Other	—		—	%	—		—	%	64,817		5	%
Total Revenues	$	1,266,208	100	%	$	1,400,040	100	%	$	1,292,613	100	%

We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.

The following table represents our revenues disaggregated by geography (in thousands):



	For the year ended December 31,
Geography	2019		2018		2017
Europe, the Middle East and Africa	$	130,530	$	134,363	$	119,934
Other Foreign	212,336		210,996		192,640
Total Foreign	342,866		345,359		312,574
United States	923,342		1,054,681		980,039
Total Revenues	$	1,266,208	$	1,400,040	$	1,292,613

Contract balances



	Contract Liabilities
Beginning balance, January 1, 2018	$	(7,066	)
Equipment revenue recognized	6,696
Equipment revenue deferred due to implementation	(4,196		)
Software revenue recognized	6,553
Software revenue deferred due to implementation	(6,269		)
Ending balance, December 31, 2018	$	(4,282	)
Equipment revenue recognized	8,807
Equipment revenue deferred due to implementation	(8,794		)
Software revenue recognized	3,953
Software revenue deferred due to implementation	(4,539		)
Ending balance, December 31, 2019	$	(4,855	)

During 2019, we recognized $3.8 million in revenue that was included in the opening contract balances for the year ended December 31, 2018. As of December 31, 2019, revenue from remaining performance obligations related to implementation of software and equipment is $3.3 million. We expect to recognize substantially all of this revenue within the next three months. Revenue from remaining performance obligations related to annual software licenses is $1.6 million. We expect to recognize substantially all of this revenue over the next twelve months.

Costs to Obtain a Contract with a Customer

As part of the cost to obtain a contract, we may pay incremental commissions to sales employees upon entering into a sales contract. Under ASC Topic 606, we have elected to expense these costs as incurred as the period of benefit is less than one year.

Practical expedients and exemptions

In addition to the practical expedient applied to sales commissions, under ASC Topic 606, we elected to apply the practical expedient for shipping and handling costs incurred after the customer has obtained control of a good. We will continue to treat these costs as a fulfillment cost rather than as an additional promised service.

Prepaids and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2019

Prepaid Expense and Other Assets, Current [Abstract]

Prepaid Expenses and Other Current Assets [Table Text Block]

Prepaid expenses and other current assets consist of the following (in thousands):



	December 31,
	2019		2018
Deposits	$	1,375	$	1,087
Other prepaid expenses and receivables	13,778		12,476
Receivables from Pfizer related to HIS business acquisition⁽¹⁾	—		20,137
Deferred costs	3,332		1,951
Prepaid insurance and property taxes	5,450		2,666
VAT/GST receivable	4,422		5,072
Deferred tax charge	1,266		1,180
Other	4,358		1,548
	$	33,981	$	46,117

Restructuring, Strategic Transaction and Integration (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 5,549	$ 1,416	$ 2,029
Restructuring Costs	8,375	4,471
Payments for Restructuring	(4,242)	(5,077)
Restructuring Reserve, Accrual Adjustment	0	(7)
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	3,878	677	915
Restructuring Costs	5,634	4,311
Payments for Restructuring	(2,433)	(4,549)
Restructuring Reserve, Accrual Adjustment	0	0
Special Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	460	739	1,114
Restructuring Costs	0	0
Payments for Restructuring	(279)	(368)
Restructuring Reserve, Accrual Adjustment	0	(7)
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,211	0	$ 0
Restructuring Costs	2,741	160
Payments for Restructuring	(1,530)	(160)
Restructuring Reserve, Accrual Adjustment	$ 0	$ 0

Acquisitions Hospira Table (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Proceeds from Issuance of Debt			$ 75,000
Business Combination, Contingent Consideration, Liability, Noncurrent	17,300		19,000
Business Combination, Consideration Transferred, Equity Issued, Fair Value	0		413,139
Business Combination, Bargain Purchase, Gain Recognized, Amount	$ 0	$ 0	70,890
Hospira [Member]
Business Acquisition [Line Items]
Payment to acquire business, net of working capital adjustments			180,785
Proceeds from Issuance of Debt			75,000
Business Combination, Contingent Consideration, Liability, Noncurrent			$ 19,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,200		3,200
Business Acquisition, Share Price			$ 140.75
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable			$ 450,400
Discount on equity issued as consideration			37,261
Business Combination, Consideration Transferred, Equity Issued, Fair Value			413,139
Business Combination, Consideration Transferred			687,924
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			31,082
Business Combination, Acquired Receivable, Fair Value			362
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			417,622
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets			13,911
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			288,134
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			131,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets			29,270
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable			12,381
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other			47,936
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			67,170
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			783,894
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent			25,080
Business Combination, Bargain Purchase, Gain Recognized, Amount			$ 70,890

Collaborative and Other Arrangements (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Collaborative and Other Arrangements [Abstract]
Fee Cap Six months subsequent to first twelve months	$ 31.3
Transitional Service Agreement Set-up Costs	22.0
Fee Cap - First Twelve Months	$ 62.5

Leases Lease Cost (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Lease, Cost [Table Text Block]

The following table presents the components of our lease cost (in thousands):



	For the year ended December 31, 2019
Operating lease cost	$	10,011

Short-term lease cost	322

Total lease cost	$	10,333

Income Taxes Deferred income tax provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Components of deferred tax provision [Line Items]
Deferred Income Tax Expense (Benefit)	$ (3,705)	$ (17,912)	$ (25,568)

Share Based Award Share awards (Notes)

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Share-based Payment Arrangement [Text Block]

SHARE BASED AWARDS

We have a stock incentive plan for employees and directors and an employee stock purchase plan. Shares to be issued under these plans will be issued either from authorized but unissued shares or from treasury shares.

We incur stock compensation expense for stock options, restricted stock units ("RSU"), performance restricted stock units ("PRSU") and in years prior to 2018 stock purchased under our employee stock purchase plan ("ESPP"), which was suspended in 2017. We receive a tax benefit on stock compensation expense and direct tax benefits from the exercise of stock options. We also have indirect tax benefits upon exercise of stock options related to research and development tax credits which are recorded as a reduction of income tax expense.

The table below summarizes compensation costs and related tax benefits (in thousands):



	Year ended December 31,
(In thousands)	2019		2018		2017
Stock compensation expense	$	21,918	$	24,241	$	19,352
Tax benefit from stock-based compensation cost	$	4,840	$	5,706	$	7,247
Indirect tax benefit	$	680	$	2,199	$	1,374

As of December 31, 2019, we had $23.6 million of unamortized stock compensation cost which we will recognize as an expense over approximately 0.8 years.

Stock Incentive and Stock Option Plans

Our 2011 Stock Incentive Plan ("2011 Plan") replaced our 2003 Stock Option Plan (“2003 Plan”). Our 2011 Plan initially had 650,000 shares available for issuance, plus the remaining available shares for grant from the 2003 Plan and any shares that were forfeited, terminated or expired that would have otherwise returned to the 2003 Plan. In 2012, 2014 and 2017, our stockholders approved amendments to the 2011 plan that increased the shares available for issuance by 3,275,000, bringing the initial shares available for issuance to 3,925,000, plus the remaining 248,700 shares that remained available for grant from the 2003 Plan. As of December 31, 2019, the 2011 Plan has 4,188,300 shares of common stock reserved for issuance to employees, which includes 263,300 shares that transferred from the 2003 Plan. Shares issued as options or stock appreciation rights ("SARs") are charged against the 2011 Plan's share reserve as one share for one share issued. Shares subject to awards other than options and SARs are charged against the 2011 Plan's share reserve as 2.09 shares for 1 share issued. Options may be granted with exercise prices at no less than fair market value at date of grant. Options granted under the 2011 Plan may be

“non-statutory stock options” which expire no more than ten years from date of grant or “incentive stock options” as defined in Section 422 of the Internal Revenue Code of 1986, as amended.

In 2014, our Compensation Committee of the Board of Directors awarded our then new Chief Executive Officer an employment inducement option to purchase 182,366 shares of our common stock and an employment inducement grant of restricted stock units with respect to 68,039 shares of our common stock. The inducement grants were made out of our 2014 Inducement Incentive Plan ("2014 Plan").

Our 2001 Directors’ Stock Option Plan (the “Directors’ Plan”), initially had 750,000 shares reserved for issuance to members of our Board of Directors, expired in November 2011. Although no new grants may be made under the Director's Plan, grants made under the Director's Plan prior to its expiration continue to remain outstanding. Options not vested terminate if the directorship is terminated.

Time-based Stock Options

To date, all options granted under the 2014 Plan, 2011 Plan, 2003 Plan and Directors' Plan have been non-statutory stock options. The majority of the time-based outstanding employee option grants vest 25% after one year from the grant date and the balance vests ratably on a monthly basis over 36 months. The majority of the outstanding options granted to non-employee directors vest one year from the grant date. The options generally expire 10 years from the grant date.

The fair value of time-based option grants is calculated using the Black-Scholes option valuation model. The expected term for the option grants was based on historical experience and expected future employee behavior. We estimate the volatility of our common stock at the date of grant based on the historical volatility of our common stock, based on the average expected exercise term. The table below summarizes the total time-based stock options granted, total valuation and the weighted average assumptions (dollars in thousands, except per option amounts):



	Year ended December 31,
	2019			2018			2017
Number of time-based options granted	6,265			5,815			8,825
Grant date fair value of options granted (in thousands)	$	424		$	425		$	375
Weighted average assumptions for stock option valuation:
Expected term (years)	5.5			5.5			5.5
Expected stock price volatility	28.0		%	24.0		%	27.0		%
Risk-free interest rate	2.2		%	2.3		%	1.1		%
Expected dividend yield	—		%	—		%	—		%
Weighted average grant price per option	$	225.27		$	269.80		$	158.20
Weighted average grant date fair value per option	$	67.73		$	73.14		$	42.51

A summary of our stock option activity as of and for the year ended December 31, 2019 is as follows:



	Shares		Weighted Average Exercise Price Per Share		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018	1,186,928		$	63.66
Granted	6,265		$	225.27
Exercised	(145,339	)	$	53.18
Forfeited or expired	—		$	—
Outstanding at December 31, 2019	1,047,854		$	66.08	4.1	$	127,556
Exercisable at December 31, 2019	1,041,589		$	65.12	4.0	$	127,556
Vested and expected to vest, December 31, 2019	1,047,854		$	66.08	4.1	$	127,556

The intrinsic values for options exercisable, outstanding and vested or expected to vest at December 31, 2019 is based on our closing stock price of $187.12 at December 31, 2019 and are before applicable taxes.

The following table presents information regarding stock option activity:



	Year ended December 31,
(In thousands)	2019		2018		2017
Intrinsic value of options exercised	$	22,976	$	51,105	$	71,283
Cash received from exercise of stock options	$	7,732	$	14,275	$	32,003
Tax benefit from stock option exercises	$	9,653	$	12,617	$	20,004

Stock Awards

In 2019, we granted performance restricted stock units ("PRSU") to our executive officers. For the executive officers other than the Chief Executive Officer ("CEO") and the Chief Operations Officer ("COO"), the PRSUs will vest subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable years. For the CEO and the COO, the performance shares will cliff-vest ending on March 6, 2022 and further subject to the achievement of a minimum Cumulative Adjusted EBITDA. If for the three year period ending on December 31, 2021 the Cumulative Adjusted EBITDA has a growth of at least 6% to 8%, 50% of the awarded units will vest. If on the vesting date the Cumulative Adjusted EBITDA has a growth of between 8% to 10%, 100% of the awarded units will vest. If on the vesting date the Cumulative Adjusted EBITDA has a growth of over 10%, 200% of the awarded units will vest. In 2019, we also granted PRSUs to one of our non-executive employees. These PRSUs will vest at the end of a three-year period ending on March 31, 2022, if certain minimum performance goals are met.

In 2018, we granted PRSUs to our executive officers. For the executive officers other than the CEO and the COO, the PRSUs will vest subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable year. For the CEO and the COO, the performance shares will cliff-vest ending on February 15, 2021 and further subject to the achievement of a minimum Cumulative Adjusted EBITDA. If for the three year period ending on December 31, 2020 the Cumulative Adjusted EBITDA has a growth of at least 6% to 8%, 50% of the awarded units will vest. If on the vesting date the Cumulative Adjusted EBITDA has a growth of between 8% to 10%, 100% of the awarded units will vest. If on the vesting date the Cumulative Adjusted EBITDA has a growth of over 10%, 200% of the awarded units will vest.

In 2017, we granted PRSUs to our executive officers. The PRSUs were scheduled to vest, if at all, upon the achievement of a minimum Cumulative Adjusted EBITDA, subject to a three-year cliff vesting ending on December 31, 2019. If at that date, our Cumulative Adjusted EBITDA is at least $600 million but less than $650 million, 100% of the awarded units will vest. If our Cumulative Adjusted EBITDA is at least $650 million but less than $700 million, 200% of the awarded units will vest. If our Cumulative Adjusted EBITDA is at least $700 million, 300% of the awarded units will vest. On January 17, 2020, the Compensation Committee made the determination that the 2017 PRSU shares were earned by our executive officers at the 300% achievement level.

In 2016, we granted PRSUs to our executive officers, which vested on December 31, 2018. During the first quarter of 2019, the Compensation Committee determined the award granted vested at 300%, as a minimum specified compound annual growth rate ("CAGR") in adjusted EBITDA per share of greater than 12% was reached for the 3-year performance period January 1, 2016 through December 31, 2018. The total number of shares of 2016 PRSUs that were earned by our executive officers was 109,110 shares.

Restricted stock units ("RSU") are granted annually to our Board of Directors and vest on the first anniversary of the grant date.

In 2019, 2018 and 2017, we granted RSUs to certain employees that vest ratably on the anniversary of the grant over three years. We recognize forfeitures as they occur.

The grant date fair market value of our PRSUs and RSUs is determined by our stock price on the grant date.

The table below summarizes our restricted stock award activity (dollars in thousands):



	Year ended December 31,
(In thousands except shares and per share amounts)	2019		2018		2017
PRSU
Shares granted	37,657		30,348		20,686
Shares earned	114,032		—		—
Grant date fair value per share	$	231.63	$	248.65	$	154.75
Grant date fair value	$	8,723	$	7,546	$	3,201
Intrinsic value vested	$	26,445	$	—	$	—

RSU
Shares granted	61,856		63,094		107,678
Grant date fair value per share	$	227.42	$	252.42	$	156.49
Grant date fair value	$	14,067	$	15,926	$	16,851
Intrinsic value vested	$	16,753	$	17,086	$	9,813

The table below provides a summary of our PRSU and RSU activity as of and for the year ended December 31, 2019:



	Number of Units		Grant Date Fair Value Per Share		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value
Non-vested at December 31, 2018	340,704		$	155.27
Change in units due to performance expectations^(a)	(14,444	)	$	238.03
Granted	99,513		$	229.01
Vested	(185,662	)	$	122.55
Forfeited	(7,584	)	$	216.29
Non-vested and expected to vest at December 31, 2019	232,527		$	205.82	0.7	$	43,510

___________________________

^(a)Relates to 2018 and 2019 CEO and COO PRSUs, assumes attainment of a reduced payout rate based on performance expectations.

ESPP

We have an ESPP under which U.S. employees may purchase up to $25,000 annually of common stock at 85% of its fair market value at the beginning or the end of a six-month offering period, whichever is lower. There are 750,000 shares of common stock reserved for issuance under the ESPP, which is subject to an annual increase of the least of 300,000 shares, two percent of the shares outstanding or such a number as determined by the Board. To date, there have been no increases. As of December 31, 2019, there were 133,487 shares available for future issuance. The ESPP is intended to constitute an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. We suspended our ESPP in 2017.

The fair value of rights to purchase shares under the ESPP is calculated using the Black-Scholes option valuation model. The table below summarizes the number and intrinsic value of ESPP share purchases and the weighted average valuation assumptions for the 2017 purchase period.




	2017
ESPP shares purchased by employees	23,426
Intrinsic value of ESPP purchases (in thousands)	$	986
Weighted average assumptions for ESPP valuation:
Expected term (in years)	0.5
Expected stock price volatility	28.1		%
Risk-free interest rate	0.6		%
Expected dividend yield	—		%

Selected Quarterly Financial Data - Unaudited (Tables)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Data - Unaudited [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]



	Quarter Ended
	Mar. 31		Jun. 30		Sept. 30		Dec. 31
	(in thousands except per share data)
2019
Total revenue	$	330,932	$	312,282	$	307,471	$	315,523
Gross profit	$	135,303	$	103,869	$	118,552	$	114,140
Net income	$	30,998	$	22,833	$	26,563	$	20,641
Net income per share:
Basic	$	1.51	$	1.11	$	1.29	$	1.00
Diluted	$	1.44	$	1.06	$	1.24	$	0.96
2018
Total revenue	$	372,033	$	360,460	$	327,169	$	340,378
Gross profit	$	149,001	$	151,800	$	134,587	$	134,640
Net income (loss)	$	4,875	$	31,054	$	219	$	(7,355	)
Net income (loss) per share:
Basic	$	0.24	$	1.53	$	0.01	$	(0.36	)
Diluted	$	0.23	$	1.44	$	0.01	$	(0.36	)

______________________________________

Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative, Gain (Loss) on Derivative, Net	$ 916	$ 743	$ 885

Revenue Contract Liabilities Text (Details) $ in Millions	12 Months Ended
Revenue Contract Liabilities Text (Details) $ in Millions	Dec. 31, 2019 USD ($)
Contract asset and liability balances [Line Items]
Contract with Customer, Liability, Revenue Recognized	$ 3.8
Equipment revenue [Member]
Contract asset and liability balances [Line Items]
Revenue, Remaining Performance Obligation, Amount	3.3
Software revenue [Member]
Contract asset and liability balances [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 1.6

Share Based Award ESPP Table (Details) - Employee Stock [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans \| shares	23,426
Stock Issued During Period, Value, Employee Stock Purchase Plan \| $	$ 986
Expected stock price volatility	28.10%
Risk-Free Interest Rate	0.60%
Expected Dividend Yield	0.00%
Expected term (years)	6 months

Income Taxes Tax Holiday (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Holiday [Line Items]
Income Tax Holiday, Aggregate Dollar Amount	$ 7.8	$ 8.8
Income Tax Holiday, Income Tax Benefits Per Share	$ 0.36	$ 0.41

Revenue Disaggregation of Revenue - Product Line (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenues	$ 315,523,000	$ 307,471,000	$ 312,282,000	$ 330,932,000	$ 340,378,000	$ 327,169,000	$ 360,460,000	$ 372,033,000	$ 1,266,208,000	$ 1,400,040,000	$ 1,292,613,000
Percentage of revenue									100.00%	100.00%	100.00%
Infusion Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues									$ 477,611,000	$ 483,039,000	$ 365,665,000
Percentage of revenue									37.00%	35.00%	28.00%
IV Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenues									$ 414,971,000	$ 507,985,000	$ 521,963,000
Percentage of revenue									33.00%	36.00%	40.00%
Infusion Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues									$ 328,282,000	$ 355,484,000	$ 290,207,000
Percentage of revenue									26.00%	25.00%	23.00%
Critical Care [Member]
Disaggregation of Revenue [Line Items]
Revenues									$ 45,344,000	$ 53,532,000	$ 49,961,000
Percentage of revenue									4.00%	4.00%	4.00%
Other Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenues									$ 0	$ 0	$ 64,817,000
Percentage of revenue									0.00%	0.00%	5.00%